Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease

Abstract

The emergence of the COVID-19 pandemic made it critical to understand the immune and inflammatory responses to the SARS-CoV-2 virus. It became increasingly recognized that the immune response was a key mediator of illness severity and that its mechanisms needed to be better understood. Early infection of both tissue and immune cells, such as macrophages, leading to pyroptosis-mediated inflammasome production in an organ system critical for systemic oxygenation likely plays a central role in the morbidity wrought by SARS-CoV-2. Delayed transcription of Type I and Type III interferons by SARS-CoV-2 may lead to early disinhibition of viral replication. Cytokines such as interleukin-1 (IL-1), IL-6, IL-12, and tumor necrosis factor α (TNFα), some of which may be produced through mechanisms involving nuclear factor kappa B (NF-κB), likely contribute to the hyperinflammatory state in patients with severe COVID-19. Lymphopenia, more apparent among natural killer (NK) cells, CD8+ T-cells, and B-cells, can contribute to disease severity and may reflect direct cytopathic effects of SARS-CoV-2 or end-organ sequestration. Direct infection and immune activation of endothelial cells by SARS-CoV-2 may be a critical mechanism through which end-organ systems are impacted. In this context, endovascular neutrophil extracellular trap (NET) formation and microthrombi development can be seen in the lungs and other critical organs throughout the body, such as the heart, gut, and brain. The kidney may be among the most impacted extrapulmonary organ by SARS-CoV-2 infection owing to a high concentration of ACE2 and exposure to systemic SARS-CoV-2. In the kidney, acute tubular injury, early myofibroblast activation, and collapsing glomerulopathy in select populations likely account for COVID-19-related AKI and CKD development. The development of COVID-19-associated nephropathy (COVAN), in particular, may be mediated through IL-6 and signal transducer and activator of transcription 3 (STAT3) signaling, suggesting a direct connection between the COVID-19-related immune response and the development of chronic disease. Chronic manifestations of COVID-19 also include systemic conditions like Multisystem Inflammatory Syndrome in Children (MIS-C) and Adults (MIS-A) and post-acute sequelae of COVID-19 (PASC), which may reflect a spectrum of clinical presentations of persistent immune dysregulation. The lessons learned and those undergoing continued study likely have broad implications for understanding viral infections’ immunologic and inflammatory consequences beyond coronaviruses.

1 Introduction

On March 11, 2020, as healthcare systems worldwide saw rising SARS-CoV-2 cases, COVID-19 was declared a pandemic (1). The infectivity of the virus and the severity of COVID-19 in many patients led to the accelerated study of the disease (2). It became increasingly apparent that the immune milieu generated by SARS-CoV-2 was unique, even among similar coronaviruses (3). Peripheral lymphopenia, elevated inflammatory markers (4), endothelial damage, and microthrombosis characterized some early findings in COVID-19 (5). In the years that followed, the immune response to COVID-19 has been further elucidated, allowing for the identification of effective vaccines (6, 7), monoclonal antibodies (8), and other therapies (9, 10). The emergence of syndromes associated with post-infectious immune dysregulation such as Multisystem Inflammatory Syndrome in children (MIS-C) (11, 12) or adults (MIS-A) (13, 14) further propelled the study of the disease. A compelling association with autoimmune disease, perhaps related to the development of autoantibodies in the presence of SARS-CoV-2-mediated pyroptosis, further exemplified the complex interplay between the immunologic response in COVID-19 and chronic disease (15).

Among the organ systems studied, a high concentration of ACE2 in a highly vascular structure readily exposed to systemic pathogens highlights the human kidney as a unique model for the systemic effects of SARS-CoV-2 (16). Prior to infection, there is a paucity of immune cells in the human kidney; most of these are CD4+ and CD8+ T cells, with a smaller percentage of NK cells, B cells (17), and CD14+, CD16+ and CD68+ myeloid cells (18). Following infection with SARS-CoV-2, an upregulation in proinflammatory genes such as HSPA1A in podocytes and JUN1 in mesenchymal clusters (19) can accompany selective immune suppression of lymphocytes mediated through T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and Programmed cell death protein 1 (PD-1) (20). Resident immune cells may mediate inflammation by TNFα release, IL-34-mediated necrosis, and NLRP3 inflammasome production (266). Myeloid cell activation is a hallmark of COVID-19 and is associated with immune dysregulation in COVID-19, particularly in severe disease (21). Moreover, early post-mortem studies revealed compelling evidence for direct infection of predominantly ACE2-positive renal tubular cells by SARS-CoV-2 (16). Intriguingly, the upregulation of TGF-β, PI3K/Akt, MAPK, and WNT signaling can be associated with tubule interstitial fibrosis and may also point to a mechanism of COVID-19-related CKD (19).

The following represents a comprehensive review of the immunologic and inflammatory consequences of SARS-CoV-2 infection, synthesizing the molecular immune response to the acute and chronic end-organ dysfunction in both acute and chronic forms of COVID-19. Among the organ systems studied, particular attention is paid to the kidney and recently described pathophysiology in COVID-19.

1.1 Initial infection with SARS-CoV-2

SARS-CoV-2 infection occurs predominantly in the upper respiratory tract via ACE2 and TMPRSS2.

Coronaviruses likely originated in bats and rodents and eventually evolved to affect other animals and humans . Their pathogenicity was not fully appreciated until 2002, when the sudden acute respiratory syndrome (SARS) broke out in Guangdong Province, China (22). Since that time, coronaviruses have been implicated in Middle East respiratory syndrome (MERS) and other less overtly severe clinical entities (22). Approximately seven years after MERS, SARS-CoV-2 emerged as a public health threat, spurring research into its structure, infectivity, and the immune response it provokes.

SARS-CoV-2 is a betacoronavirus with an envelope containing an envelope (E) protein, a membrane (M) protein, and a spike (S) protein interspersed within a lipid membrane (5). The nucleus contains a positive-sense single-stranded RNA molecule bound to the nucleocapsid (N) protein (23). The bulk of the ssRNA has two open reading frames at the 5’ end, ORF1a and ORF1b, which are the transcriptional precursors of the viral replication and transcription complex (RTC) (23). SARS-CoV-2 is transmitted by respiratory and aerosolized droplets from infected individuals actively shedding the virus (24–26). Virions can contact areas of high angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) co-expression, namely in goblet secretory cells in the nasopharynx, epithelial cells of the oral mucosa, airway, and alveoli including Type II pneumocytes, and lung macrophages (27, 28). Viral entry into host cells is facilitated by binding the S protein to ACE2, followed by proteolytic cleavage at the S1/S2 and S’ sites by TMPRSS2, a process that allows for virus-host membrane fusion (29). Expression of ACE2 and TMPRSS2 has also been noted in endothelial cells, enterocytes (27), and podocytes in the kidney glomerulus (5).

The importance of ACE2 has been confirmed through GWAS identification of variants (such as X-linked rs190509934) associated with reduced ACE2 expression and reduced likelihood of infection with SARS-CoV-2 (30, 31). Likewise, increased susceptibility to infection is associated with SLC6A20 on chromosome 3p21.1, which encodes a protein [sodium-imino acid transporter 1 (SIT1)] that is associated with ACE2 (30, 31). Dipeptidyl peptidase-4 (DPP-4) has been identified as another possible candidate for SARS-CoV-2 binding in silico, albeit of unclear clinical significance (32–36). In addition to TMPRSS2, proteolysis can also be performed by endosomal cathepsin B (catB) and cathepsin L (catL) (23). Following fusion, the release and subsequent translation of ORF1a and ORF1b lead to the production of polypeptides pp1a and pp1ab, which are eventually processed into 16 non-structural proteins that comprise the viral RTC (23) (Figures 1A, B). Structural proteins are encoded from interspersed ORFs at the 3’ end of the ssRNA and are eventually processed in the endoplasmic reticulum and Golgi apparatus with modifications including N- and O-glycosylation, which are thought to be critical to virion infectivity (23, 37). Among the proteins produced during acute infection are replicase proteins, which help form replication complexes within the endoplasmic reticulum (38).

Figure 1

One mechanism of protection from pattern recognition receptors (PRRs), such as melanoma differentiation-associated protein 5 (MDA5), includes the formation of double-membrane vesicles (38). Relatively unchecked viral replication and an immune response that can be in disarray in severe disease can lead to the eventual dissemination through deeper inhalation of upper respiratory virus-containing particles or contiguous spread from the site of infection (38). Further dissemination of SARS-CoV-2 to other organ systems can be mediated through viremia, which is associated with adverse clinical outcomes (39). SARS-CoV-2 can evolve within a host to develop enhanced infectivity, immune evasion, and transmissibility, all of which can translate to pathogenicity and disease severity on the individual and population levels (40). A mutation rate of approximately 1 × 10^–6 to 2 × 10^–6 mutations per nucleotide per replication cycle is one characteristic of SARS-CoV-2 evolution (40). Selection pressures such as innate immune defense mechanisms like those mediated by the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) family provoke the formation of C->U mutations, which can alter phenotypic properties of the virus , which can, in turn, lead to the development of variants of concern (VOC). Transmissibility resulting from molecular evolution represents a bottleneck for mutations to pass from one host to another and in turn the likelihood of a virus like SARS-CoV-2 to cause an epidemic or pandemic (40). As a virus enters and uses the host cell for its own propagation, a response is elicited in the human host to fight for its own preservation. In the subsequent sections, that response—characterized by distinct but often overlapping cellular and extracellular mechanisms that accompany each stage of infection with SARS-CoV-2—will be elucidated.

2 Acute immunologic and inflammatory response to SARS-CoV-2

2.1 Innate immune responses to acute infection with SARS-CoV-2

The innate immune response to SARS-CoV-2 is the first line of defense against the virus (41) and also represents a crossroad at which immune cell recruitment and coordination can be pathologically skewed. Inflammatory cytokine disarray with concomitantly delayed IFN-I and IFN-III responses may be primary mediators of immune dysregulation in severe disease (42). Dysregulated innate immune responses comprise one of the critical features of COVID-19 (42).

2.1.1 Host cell viral recognition

Early pattern recognition receptor and Toll-like receptor activation in SARS-CoV-2.

In normal physiologic conditions, the entry of viral RNA into a host cell does not go unnoticed. The newly released viral ssRNA contains pathogen-associated molecular patterns (PAMPs) recognized as foreign entities by pattern recognition receptors (PRRs) in the cytoplasm and along the cell membrane and endosomal surfaces (43–45). PRRs include cytoplasmic retinoic acid-inducible gene I-like receptors (RLRs) and membrane-bound Toll-like receptors (TLRs), with subclasses that recognize a wide array of viral nucleic acid assortments (44, 45). As a positive-sense ssRNA, the viral RNA from SARS-CoV-2 is recognized by the RLRs retinoic acid-inducible gene (RIG-I) and MDA5 by its uncapped 5’ triphosphate terminus (43). The activation of RIG-I and MDA5 and their association with mitochondrial antiviral signaling protein (MAVS) eventually leads to the transcription of type I interferons, which are likely dependent on nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) (45).

Positive-sense ssRNA also activates endosomal TLR7 (as well as TLR8), which, in conjunction with myeloid differentiation primary-response gene 88 (MyD88), typically leads to the production of both type I and type III interferons (IFNs) (46, 47). The TLR7/MyD88 pathway mediates immunity in plasmacytoid dendritic cells (pDCs) in multiple viral infections and is also likely relevant in airway epithelial cells infected with SARS-CoV-2 (48, 49). Furthermore, the severity of illness in young male patients with loss-of-function variants in the X-linked TLR7, as well as the associated defects in type I and type II interferon production, suggest a critical role of this pathway in the innate response to SARS-CoV-2 infection (46). Endosomal TLR3 may also be activated in the presence of SARS-CoV-2, perhaps due to transient dsRNA produced in the viral replication process (43, 49). TLR3 binds to TIR-domain-containing adapter-inducing interferon-β (TRIF), which also can lead to type I and type III interferon production via IFN regulatory factor 3 (IRF3) as well as robust NF-κB activation (43, 45, 50). MyD88 activation can polarize macrophages towards a pro-inflammatory M1 phenotype in mouse models (51). In addition to the above mechanisms, human airway epithelial cells infected with SARS-CoV-2 have also been shown to have decreased transcription of dual-specificity phosphatase 1 and 5 (DUSP1 and DUSP5), which may lead to unbalanced activation of NF-κB (52).

2.1.2 Compounded inflammation in acute SARS-CoV-2 infection at the level of the host cell

SARS-CoV-2 provokes the release of pro-inflammatory cytokines via NF-κB, inflammasome production, and pyroptosis.

Cytopathic viral infection of airway epithelial cells can trigger inflammasome activation, pyroptosis, necroptosis, and apoptosis (28, 53–55). Early studies during the pandemic revealed intense NLRP3 inflammasome expression in the lungs of patients with fatal COVID-19 (56), suggesting a pivotal role for pyroptosis in severe COVID-19 (57). SARS-CoV-2 may promote pyroptosis through non-structural protein 6 (nsp6) (58). The subsequent release of damage-associated molecular patterns (DAMPs) and activation of IL-1β may be one of the first events leading to the inflammatory cascade that characterizes COVID-19 (28). The release of DAMPs and IL-1β promotes the release of additional inflammatory cytokines such as macrophage inflammatory protein 1α (MIP1α), MIP1β, IL-6, and interferon gamma-induced protein 10 (IP-10) from adjacent alveolar macrophages, epithelial cells, and endothelial cells (28, 59). TGF-β production may also be enhanced in severe disease (60).

An essential function of ACE2 is to degrade angiotensin II (Ang II) into Ang- (1, 7, 61). As SARS-CoV-2 binds to ACE2 and the complex is endocytosed or incorporated through other mechanisms (62), less ACE2 is available to perform its typical functions, and levels of Ang II rise. The increasing levels of Ang II provide excess stimulation to the Ang II Type 1 receptor (AT1R), which—in addition to vasoconstriction—promotes the activation of NF-ĸβ through ADAM17 cleavage of TNFα, membrane-bound EGF (63), and IL-6Rα into their soluble forms (61). Subsequent activation of TNFαR and EGFR also leads to downstream NF-κB activation (61, 63). The activation of gp130 by the IL6R-α-IL-6 complex further activates a JAK/STAT pathway, amplifying the NF-κB response via STAT3 (63).

NF-κB plays a pivotal role in the upregulation of the immune response (64). It has been hypothesized that the benefits of corticosteroids such as dexamethasone may be partially due to the downregulation of NF-κB pathways (65). In airway epithelial cells, NF-κB promotes the production of IL-6, G-CSF, GM-CSF, and MIP2 kβ (66). In M1 alveolar macrophages, NF-κB promotes the production of an array of inflammatory cytokines, including IL-1β, IL-6, IL-12, and TNFα (64). NF-κB in SARS-CoV-2-infected hosts has also been shown to trigger NLRP3 (57) inflammasome formation and pyroptosis in monocytes through a caspase-1 mechanism with resultant production of DAMPs and cytokines such as IL-1β (67, 68). DAMP-mediated signaling itself leads to a conformational change in NLRP3 and caspase-1-mediated cleavage of the inhibitory C-terminus of gasdermin D, which is the main effector of pyroptosis (57). Gasdermin D can then traffic to the cell membrane and polymerize into β-barrel pores, promoting ion (namely, Ca2+) and protein flux and the eventual loss of the mitochondrial membrane potential and IL-1 and IL-18 activation and IL-1β release (57).

Other cytokines include IL-2, IL-17, IL-8, macrophage inflammatory protein 1 (MIP-1), monocyte chemoattractant protein 1 (MCP-1), and chemokine ligands (e.g. CCL2, CCL3, and CCL7) including C-X-C motif chemokine ligands (e.g. CXCL2 and CXCL10) (65). The clinical significance of cytokine release was demonstrated in a 2021 single-cell and bulk RNA-seq analysis of specimens from patients with COVID-19, which showed that upregulation of IL-2, IL-6, IL-8, IL-17A, and NF-κB was correlated with the severity of COVID-19 (69). The function of several such cytokines and chemokines in COVID-19 are summarized in Table 1. The release of cytokines in COVID-19 is associated with a hyperinflammatory state, leading to what some have called a “cytokine storm” that characterizes severe COVID-19 and its associated end-organ dysfunction syndromes (61, 63), similar to that seen in other hyperimmune responses characterized by cytokine release syndromes (CRS) related to chimeric antigen receptor-modified T (CAR-T) cell therapy, macrophage activation syndrome (MAS), and hemophagocytic lymphohistiocytosis (HLH) (70, 71).

Hyperinflammatory immune responses are not necessarily unique to SARS-CoV-2 (72, 73): High levels of IL-6 have been noted in patients with acute respiratory distress (ARDS) before the COVID-19 pandemic (74). Others have suggested that lymphocyte depletion and exhaustion, delayed interferon response, and decreased TNFα production in certain phases of the disease are indicators of immune suppression (75). Although a more precise depiction of the cytokine-mediated inflammatory response in COVID-19 may be suggested by the term “cytokine disharmony” or other terms denoting dysregulation, by and large, the immune response in severe forms of COVID-19 appears to skew towards a hyperinflammatory cytokine dysregulation (76–81), with early outcomes in severe disease perhaps attributable to cytokines preferentially elevated in SARS-CoV-2 (73, 82), interferon I dysregulation (83), and local microthrombi formation (74, 84), as will be discussed in further detail.

2.1.3 The role of interferons

Interferon release is suppressed early in the course of SARS-CoV-2 infection.

Interferons are integral to the antiviral immune armamentarium and have been shown to have potent anti-SARS-CoV-2 activity (85). Critical illness in COVID-19 is associated with inborn errors of genes involved in Type I interferon production (86). While IFN-α and IFN-β can contribute to inflammation in SARS-CoV-2 through IFNR-mediated downstream activation of NF-κB, the simultaneous stimulation of interferon-stimulated genes (ISGs) can promote the development of a potent antiviral state (87, 88). First, IFN acts to increase PRRs, which can improve viral detection (88). In tandem, many proteins are produced via ISGs, which can inhibit nearly every step in viral infection and replication (88).

Despite their seemingly potent anti-SARS-CoV-2 activity, the transcription of crucial interferon genes for type I and type III interferons (IFNB, IFNK, IFNA5, and IFNL1-5) is suppressed early in the course of SARS-CoV-2 infection, particularly in severe disease (42, 89). Mechanisms may include suppression of sequential steps along the pathway of ISG production, similar to that mediated by other coronaviruses such as SARS-CoV-1 [mediated in part by Nsp1 (90)] and MERS-CoV in humans and murine hepatitis virus (MHV) in mice (91–93). This phenomenon, among others, may help to explain the pathogenicity and associated immune dysregulation of SARS-CoV-2 (85, 89, 94, 95).

2.1.4 Soluble pattern recognition molecules

Soluble pattern recognition molecules (PRMs) have antibody-like functions representing a key component of humoral immunity (96). These include collectins (e.g., mannose-binding lectin (MBL), which activates the complement system via the lectin pathway), pentraxins [e.g., C-reactive protein (CRP)], C1q, and ficolins (96). Systemic complement activation was upregulated in patients with COVID-19, with sC5b-9 and C4d found to be higher in those patients with respiratory failure (97). A 2022 study revealed that MBL and pentraxin 3 (PTX3) play critical roles in humoral immunity against SARS-CoV-2, with MBL binding to spike (S) protein in a glycan-dependent manner prompting complement activation via the lectin pathway and with PTX3 binding to nucleocapsid (96) (Figure 1J). Furthermore, single nucleotide polymorphisms (SNPs) of the MBL2 gene, particularly rs10824845, suggest an association with the severity of COVID-19 (96). Interestingly, despite its apparent association with clinical outcomes, CRP was not shown to bind to any of the SARS-CoV-2 proteins tested, which included S, N, and E (96, 98).

2.1.5 Monocytes and macrophages

Monocytes and macrophages play a prominent role in the dysregulated immune response to SARS-CoV-2 (71). Macrophages express ACE2 receptors and represent targets for SARS-CoV-2 viral entry [which may also occur via the Fc receptor CD16 (99)], viral replication (99) and spread (100, 101), and associated immune responses (102). Responsiveness to TLR associated with suppressing IL-1R-associated kinase (IRAK)-M expression points to hyperinflammatory phenotype (102). Macrophages mediate cytokine release in COVID-19 through STAT1 signaling and pDC activation and may be associated with a dampened IFN-I response (103, 104). Once activated during SARS-CoV-2 infection, macrophages showed signs of inflammasome activation as evidenced by an associated speck-like protein containing a CARD (ASC) co-localization with NLR family pyrin domain containing 3 (NLRP3) and activated caspase-1, as shown in a recently published in vivo murine model with a humanized immune system (99). IL-18 and IL-1RA (considered downstream evidence of inflammasome activation) were upregulated (with IL-1β also evident in vitro), as was chemokine CXCL10 expression (99). Finally, pyroptosis was also increased in this model as measured by LDH and gasdermin D levels (99). Similar results were seen in in vitro studies of monocytes (67). IL-6 further promotes the differentiation of monocytes to macrophages (70). Perhaps owing to the ubiquity of macrophages in tissues (105), macrophage-induced inflammation—mediated in part by direct viral infection, inflammasome activation, pyroptosis (57), and cytokine release (70, 103, 104)—appears to be a prominent driver of the SARS-CoV-2-mediated immune response (101, 106) (Figures 1C–F).

2.1.6 Plasmacytoid dendritic cells

Plasmacytoid dendritic cells (pDCs) help drive the immune response to viral infections such as coronaviruses (107). pDCs are more likely to be directly infected with SARS-CoV-2 than macrophages (104), and emerging evidence has shown that pDCs are the predominant cell type involved in the production of Type I and Type III interferons (108). COVID-19 severity is inversely correlated with a pDC-driven IFNα response (108). The presence of pDCs was seen in the lungs of patients with SARS-CoV-2 and was associated with IFN-I signaling, itself correlated with macrophage inflammatory response (104). pDCs have been shown to enhance TLR signaling in macrophages via IFN-1; RNAseq studies have additionally shown mediation of transcriptional changes in macrophages that correlate with a more robust inflammatory response to SARS-CoV-2 than to LPS (104). A 2021 study showed that both myeloid and plasmacytoid dendritic cells show an alteration in DC homing and activation markers such as PDL-1, CD86, and CCR7 that correlated with hospitalization status (109). Given the central importance of macrophages in COVID-19, the mechanistic pathways involving pDCs are likely a critical first step in developing the hyperinflammatory cytokine response accompanying macrophage activation in severe disease. Functional alterations of DCs and deficiency of pDCs (as well as CD1c+ mDCs) may persist seven months after acute SARS-CoV-2 infection (109).

2.1.7 Neutrophils

In addition to their overt role in bacterial and fungal infections, neutrophils can contribute to the immune response to viruses (110). They may additionally exhibit enhanced trafficking to highly vascularized organs such as the lungs and kidneys (111). Neutrophilia (112) and a high neutrophil-to-lymphocyte ratio are associated with severe COVID-19 (113, 114). Early studies using single-cell transcriptomics and proteomics from peripheral blood mononuclear cells (PBMC) of patients with COVID-19 showed altered myelopoiesis in patients with severe disease (115). Immature neutrophils expressing CD24, DEFA3, DEFA4, and PGLYRP1 were a prominent cell population in that study (115). Another study showed a reduction in the neutrophil maturation marker CD-10, associated with emergency myelopoiesis (400) and poor clinical outcomes (116). Among the mechanisms studied, the formation of neutrophil extracellular traps (NETs) (aggregates of extracellular DNA, histones, neutrophil elastase, myeloperoxidase, and other molecules such as tissue factor) (111) are thought to play a prominent role in COVID-19 pathogenesis, mediated in part through target-organ microvascular occlusion (111) and associated immunothrombosis (111, 117) (Figure 1I).

2.1.8 Natural killer cells

Acknowledging the innate-adaptive overlap exhibited by natural killer (NK) cells (118), NK cells play an essential role in innate antiviral responses (119, 120). While an increased frequency of activated NKG2C⁺CD57⁺ CD56^dim NK cell phenotypes may be seen in severe COVID-19 (121), severe infection is associated with peripheral NK cell depletion and an exhausted phenotype based on LAG3, PDCD1, and HAVCR2 expression, which may be mediated by aberrant TGF-β production and homing to lung tissue (121, 122). NK cell quiescence manifesting as decreased perforin and granzyme production has also been demonstrated in COVID-19. This may be mediated by increased IL-6 (123) and TNFα, both part of the cytokine milieu characterizing the syndrome (124).

2.1.9 Innate lymphoid cells

Innate lymphoid cells (ILC) are more recently described subsets of lymphocytes that can participate in innate immune responses that mirror type 1, type 2, and type 3 immune responses (125). Studies have shown that illness severity in COVID-19 is inversely associated with ILC count (126, 127). ILC-mediated amphiregulin production has been proposed as one mechanism of immune tolerance (126). Of note, a proportionally higher number of amphiregulin-producing ILC was seen in healthy controls vs patients hospitalized with COVID-19 and in females versus males (126).

2.1.10 Mucosal-associated invariant T-cells

Mucosal-associated invariant T-cells (MAIT) are innate-like T cells that recognize non-specific riboflavin metabolites of bacteria at mucosal surfaces, including those lining the bronchial tree, which are also activated during viral infections (128, 129)and can inhibit viral replication (130). While the specificity and significance of this cell type in COVID-19 is still under study, heightened activation of circulating CD8+ MAIT cells (127, 128) may correlate with illness severity as measured by Simplified Acute Physiology (SAPS) II score (128).

2.1.11 γδ-T-cells

γδ-T-cells are another subset of T-lymphocytes with innate-like functionality with the potential to induce strong antiviral responses independent of MHC-mediated antigen presentation (122, 131, 132). Their use in cancer immunotherapy (122, 133) and presence at mucosal barrier sites (134) stimulated interest in their role in COVID-19 (133, 134). In SARS-CoV-1, they appear to be active members of the immune milieu (133, 135). However, their role in SARS-CoV-2 appears to be muted (131) compared to SARS-CoV-1¹²⁰. In addition to their peripheral depletion, as with other T-cell subsets (136), γδ-T cells could not mount a potent immune response to spike or nucleocapsid antigen in vitro studies (131). The depletion of various innate-like lymphocyte subtypes is portrayed as a component of the early immune response to SARS-CoV-2 in Figure 1K.

2.2 Adaptive immune responses to SARS-CoV-2 infection

Components of the innate immune response to SARS-CoV-2 infection can help in the immediacy of their response while simultaneously perpetuating detrimental non-specific inflammatory signaling. The adaptive immune response generally follows the innate immune response and provides an additional layer of nuanced and potentially potent protection in patients with and recovering from COVID-19. In addition, the memory adaptive response induced by both natural infection and vaccination, as discussed below, plays a crucial role in protection from reinfection, limiting disease severity and hastening resolution in the event of reinfection.

The adaptive immune response plays an important role in viral infections, primarily consisting of CD4+ T-cells, CD8+ T-cells, and B-cells (137). Despite this role, lymphopenia is a hallmark of COVID-19 and may correlate with disease severity and severe lung injury (127, 138, 139) (Figure 2A). In addition to the direct cytopathic effects of SARS-CoV-2 (140), early studies showed significant damage to lymphoid tissue and lymphocyte apoptosis in the lymph nodes and spleen of deceased patients with COVID-19 (141). Additional mechanisms may involve sequestration or recruitment of lymphocytes to actively inflamed tissues such as the lung and other target organs (127, 142). Lymphopenia also appears to be inversely related to levels of IL-6 and therapeutically targeted IL-6 inhibition can lead to the correction of circulating lymphocyte counts (143, 144).

Figure 2

2.2.1 CD4+ T-cells

CD4+ T-cells are integral to developing a targeted adaptive immune response by recognizing foreign antigens on MHC Class II molecules and activating other immune cells, including CD8+ T-cells, B-cells, and NK cells (145). Specific viral targets of CD4+ T-cells include M, N, and S, nsp3 and ORF3, and others, albeit to a smaller degree (137, 146). Tan et al. and others showed that a robust CD4+ T-cell response is important for viral clearance in SARS-CoV-2 (147) and that the relative absence of such a response could be fatal (148). Early studies showed a more prominent CD4+ T-cell response than CD8+ T-cells (137), with increased expression of CD38 in moderate-to-severe disease indicative of an activated phenotype (149). An increased proportion of cytotoxic CD4+ T helper (CTL-T_H) cells and follicular T_FH-cells (which have a role in B-cell affinity maturation and antibody production) were seen in hospitalized patients with COVID-19 relative to regulatory T-cell (T_reg) populations (145). Curiously, another study showed a positive correlation of specifically CD8+ T_reg cells with increased CD4+ cells in patients with acute SARS-CoV-2 infection (150), a finding potentially indicative of a compensatory anti-inflammatory program (89).

As noted, depletion of T-cells, particularly in the peripheral blood, is a hallmark of severe COVID-19 (144, 149). T-cells exhibit enhanced expression of apoptotic pathways and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) and programmed cell death protein 1 (PD-1), which—while expressed in activated states—can also be markers of T-cell exhaustion (139). In addition, germinal centers—which are important sites of T-cell and B-cell interaction—are lost in thoracic lymph nodes of patients with acute COVID-19, with an associated loss of germinal center CD4+ Bcl-6+ T_FH-cells and an increased proportion of T_H1-cells (151), which are responsible for IFNγ production. Bcl-6 is a transcriptional repressor that can allow for the development of high-affinity immunoglobulins in both T and B-cells (152). Taken together, T-cell lymphopenia, exhaustion, and associated immune sequelae likely contribute to the immune dysregulation in COVID-19 (Figure 2B).

2.2.2 T_H17 cells

T_H17 cells are a distinct lineage of CD4+ T-cells that are typically involved in the clearance of extracellular pathogens (153). Their differentiation is mediated through TGF-β and IL-6 (153), both of which are upregulated in severe COVID-19 (60, 154). T_H17 cells may contribute to acute inflammation in COVID-19 through the release of IFN-γ, GM-CSF, IL-10, IL-17A, IL-17F, IL-21, and IL-22 (155) (Figure 2B). An increased T_H17/T_reg ratio and their associated factors (e.g., RAR-related orphan receptor gamma (RORγt)/Forkhead box protein P3 (FoxP3) appear to correlate with SARS-CoV-2 infection as well as clinical outcome (156). As will be discussed, T_H17 cells have been implicated in chronic autoimmune and inflammatory conditions and thus may represent an important link between acute and chronic immunity in patients with COVID-19 (153).

2.2.3 CD8+ T-cells

CD8+ T-cells target cells infected with intracellular pathogens, including viruses such as SARS-CoV-2, by detecting foreign antigens on MHC-1 (137, 157). CD8+ T-cells can target numerous proteins derived from SARS-CoV-2, depending on expressed HLA class I types (146). While widely viewed as critical for disease resolution and subsequent protection from re-infection (137), SARS-CoV-2-specific CD8+ T cell responses in the blood tend to be relatively low in frequency (compared to influenza or Epstein-Barr virus) in most infected or resolved individuals (158). Several studies have confirmed a decrease in circulating CD8+ T-cells in COVID-19 (139, 144, 159, 160). Those CD8+ T-cells that were present were found to be highly activated in a subset of COVID-19 patients as measured by KI67 and HLA-DR+CD38 expression (161) and appear to retain their cytotoxic capacity as measured by IFNγ, granzyme B, perforin, and CD107a production or expression (137) (Figure 2C). In addition, pre-existing cross-reactive nucleocapsid-specific memory CD8+ T-cells that recognize seasonal coronaviruses (162) may provide some level of protection from primary SARS-CoV-2 infection or disease severity, depending on the specificity and HLA haplotype. CD8+ T-cells have also been implicated in non-COVID cytokine release syndromes such as macrophage activation syndrome (MAS) (163) and may play a similar role in the exacerbated immune response in COVID-19.

2.2.4 Memory T-cells

Memory T-cells can recognize and aid in clearing viruses to which a host may be re-exposed (164). Given the novelty of SARS-CoV-2, the duration of detectable memory T-cells responsive to SARS-CoV-2 remains the subject of ongoing study. Highly reactive, polyclonal CD8+ T-cells have been detected in the serum of patients with a history of mild COVID-19 up to one year after infection (165), with recent studies supporting at least this duration for SARS-CoV-2-specific CD8+ T-cells expressing CD45RA, IL-7R-α, T cell factor 1, and low CCR7 (166). This phenotype suggests tissue recirculating effector memory CD8+ T cells that retain high proliferative potential yet traffic through lymphoid and non-lymphoid tissues (167). Of note, memory T-cells have been detected in patients with SARS-CoV-1 beyond 17 years (164). Importantly, SARS-CoV-2-specific stem-cell-like memory T-cell populations appear to be maintained regardless of disease severity (164) (Figures 2F, G). While the clinical significance of memory cell phenotypes remains to be determined, particularly in the context of viral variants (89), evidence suggests that CD8+ T-cells generated through natural immunity (168) or vaccination (169) can cross-recognize viral antigens despite a significant number of mutations in the viral genome (169).

2.2.5 B-cell-mediated immune response: humoral immunity

B-lymphocytes are a critical component of adaptive immunity. Antibodies secreted by B-cell-derived plasma cells can serve multiple roles through antigen binding: Neutralization by preventing pathogen entry, immune cell recruitment and/or activation, and enhancement of antigen uptake and processing by antigen-presenting cells to other immune cells (170). Antibodies have also historically provided a measurable immune response that can serve as an imperfect but established benchmark for immunity (170–172).

2.2.6 Naturally occurring antibodies

Pre-existing antibodies to SARS-CoV-2 in humans were predominantly non-neutralizing, directed towards the N-protein and, to a lesser extent, the largely conserved S2 component of the S protein, which does not contain the receptor binding domain (RBD) (173, 174), with the latter suggesting some degree of cross-reactivity from endemic coronaviruses (174, 175) (Figure 1G). Anti-glycan antibodies—by and large of the IgM class (176)—may also be found in humans at baseline and can be targeted towards glycans found on enveloped viruses (176). Lower risk of COVID-19 in patients with blood type O (177) may have contributed to the hypothesis that certain blood types may be more protective against SARS-CoV-2 infection, perhaps by anti-glycan ABO antibodies (177). Early GWAS of COVID-19 patients provided a biologically plausible mechanism for this proposed phenomenon by identifying a reproducible association of susceptibility to COVID-19 with locus 9q34.2, which coincides with the ABO locus (178, 179). However, observational data since the discovery of the virus have been mixed (176, 180), perhaps owing to the difference between susceptibility and clinical severity of the disease (179).

2.2.7 Acute B-cell response to SARS-CoV-2 Infection

The acute phase of SARS-CoV-2 infection is accompanied by B-cell lymphopenia and early plasmablast development from extrafollicular sites, a response typically occurring within 3-5 days (173, 181). In contrast to other infections, early antibody responses to SARS-CoV-2 include IgG, IgA, and IgM production (173) directed predominantly toward the N and S proteins (173). Somatic hypermutation and affinity maturation are less likely to occur at this stage (173, 181), and plasma cells produced during this time tend to be short-lived (173). The degree of extrafollicular B cell activation is characterized by an increase in CD11c⁺ activated naive (aN) B-cells which are precursors to IgD^-CD27^-, C-X-C chemokine receptor type 5 (CXCR5)^-CD21^- [double-negative 2 (DN2)] B-cells in addition to more recently discovered Cd11^-CD21^- (DN3) B-cell populations in severe COVID-19, which correlates with an increase in antibody-secreting cell populations (181) (Figure 2D). The differentiation of these cells is TLR7-independent and is mediated through IFNγ-IL-21 interactions, with the increase in DN2 B-cells additionally found to correlate with levels of IL-6 and IP-10 (181). Notably, an increase in endogenous neutralizing antibodies correlates with severe disease (181) and thus may suggest a raging battle rather than a victorious immune response. Curiously, a similar B-cell activation phenotype has been found in active SLE (181).

Approximately seven days after infection (181), a more nuanced and durable B-cell follicular response begins to develop from germinal center (GC) cells in lymphoid tissue via class-switching, affinity maturation, and somatic hypermutation (173). IgM and IgG anti-N, anti-S (182), and specifically anti-RBD (183)-defined seroconversion typically occur at a median of 11-13 days after symptom onset (173, 182, 183). In severe COVID-19, however, the GC response may be markedly blunted: Post-mortem specimens revealed an absence of germinal centers in the thoracic lymph nodes of patients with acute COVID-19 (151). A reduction of Bcl-6⁺ GC B-cells was seen in the same patient population (151). As previous research points to a quantitatively robust and seemingly adequate neutralizing capacity of the early extrafollicular antibody response (181), it is conceivable that the sustained production of meticulously targeted antibodies may be adversely impacted. However, the mechanism underlying this relationship likely requires further study (184).

2.2.8 Memory B-cells

Memory B-cells (MBCs) provide an immune reservoir for clonal expansion after infection (185, 186). In acute SARS-CoV-2 infection, the extrafollicular B-cell response includes the development of transient non-class-switched MBC with low rates of somatic hypermutation and class-switching (173). In tandem, pre-existing MBC populations with cross-reactivity to conserved S2 regions can proliferate, as evidenced by a robust initial IgG response to S2 (174). B-cells that enter germinal centers of secondary lymphoid organs can develop a more nuanced immune memory through class switching and somatic hypermutation later in the course of infection (173). Patients who recover from COVID-19 have an increased proportion of tissue-like memory (TLM) IgG+ S1-specific MBC (187) and circulating resting IgDloCD20+ MBC sustained for at least seven months after acute infection (188) (Figure 2H). The process of MBC generation likely requires CD4+ T-cells and can be affected by the severity of illness (187). Among the various immunoglobulin subtypes, IgG MBC eventually predominates in recovered individuals, along with a minor population of IgA MBC (171, 173).

2.2.9 Long-lived bone marrow plasma cells

Long-lived CD19⁻CD38^hiCD138⁺ bone marrow plasma cells (BMPC) are another component of the humoral memory (173, 189) and may be the primary source of circulating antibodies years after a viral infection (188). Their presence has been detected at least seven months following infection with SARS-CoV-2 (188).

A summary of several important cell types and their function in acute and post-acute COVID-19 is shown in Table 2. Of note, while neutralizing antibody titers may suggest protective immunity early in the post-infectious period (172), the relative contributions of various immune memory cells to sterilizing or protective immunity in SARS-CoV-2 remain the subject of further study, making such immunity challenging to define at this time.

2.2.10 Vaccine-mediated adaptive immunity

The severity of the COVID-19 pandemic spurred the development of highly effective vaccines with the benefit of low-risk immunity across a population. Currently, available SARS-CoV-2 vaccines contain mRNA (or DNA in adenovirus vaccines) encoding the S protein, which can be further cleaved into its subunits S1 and S2 (190). Initial studies with mRNA vaccines established immunogenicity based on clinical efficacy (6), IgG response to RBD or S1, and at least 50% neutralization titers (191). Later studies further showed the durability of vaccine-induced immune memory, as evidenced by an increase in CD71+ MBC cells 3-6 months post-vaccination, even as antibody levels to S and the RBD declined (192). Notably, MBCs were cross-reactive to alpha, beta, and delta variants per data available then (192). More recent findings highlight the effect of sequential vaccine boosters as promoting refined MBC antibody-mediated immunity that targets both the ACE2 binding site of SARS-CoV-2 spike protein as well as more conserved components of the RBD (i.e., Type 1/4 antibodies), which correlate with increasing potency of SARS-CoV-2 neutralization (185).

While not suited for neutralizing and preventing viral entry into host cells, T-cell responses can help prevent the spread of infection within a host and consequently can impact illness severity and virus transmissibility (193). Omicron variant vaccine efficacy has been shown to be adversely affected by Omicron-specific CD8+ T-cell responses despite moderate levels of neutralizing antibodies in macaques (194). More recent studies also suggest conserved vaccine-mediated cellular immunity across variants, including Omicron, despite a diminished neutralizing antibody response (195). While the authors would be remiss if we did not mention vaccine-mediated immunity, the topic itself warrants further exploration beyond this paper’s scope.

The immune response evoked by infection with SARS-CoV-2 at the molecular level is often accompanied by the clinical syndrome known as COVID-19. COVID-19 is widely recognized as a predominantly respiratory disease manifesting as fever and cough (196). It is also recognized that the virus and its inflammatory response can affect multiple organ systems outside of the respiratory tract, as described in the following section.

2.3 Acute immune-mediated end-organ injury following SARS-CoV-2 infection

Acute SARS-CoV-2 infection can lead to end organ damage through direct viral infection associated with localized immune activation and systemic immune responses. In addition to the lung, ACE2 receptors can be found in the heart (197), brain (198), kidney (199), testis (199), liver (200), colon (199, 201), and other organs (199, 202) (Figure 3A). While the clinical significance of such expression has not yet been fully elucidated, SARS-CoV-2 viremia can lead to end-organ infection and associated dysfunction by developing local pathologic inflammatory responses. Furthermore, the presence of ACE2 on endothelial cells (203, 204) and the known association with endotheliitis (197, 205) and microthrombi (203, 206) may allow for SARS-CoV-2 to affect multiple organs through disruption of the normal functioning of the microvasculature (197).

Figure 3

2.3.1 Endothelial cell infection, microangiopathy, and microthrombi mediate end-organ dysfunction in COVID-19

ACE2 expression on endothelial cells may allow for viral infection to impact multiple organs, including the lung and kidney (207). Early pathologic specimens from COVID-19 patients revealed direct viral infection of endothelial cells in a transplanted kidney, with inflammatory lymphocytic infiltration noted in microvasculature of the heart, lung, kidney, and liver (207). While endotheliitis and hypercoagulation can be found with other viral infections, additional studies revealed the presence of intracapillary microthrombi in the pulmonary vasculature, as well as intussusceptive angiogenesis likely resulting from loss of normal microvascular architecture, which was seen more often in SARS-CoV-2 when compared to H1N1 influenza A (208, 209). Endothelial cell activation is associated with a hypercoagulable state in COVID-19 (210, 211), with proposed mechanisms including exocytosis of granules containing von Willebrand factor (vWF) and P-selectin (211) in addition to alteration in plasminogen activator inhibitor 1 (PAI-1) and tissue factor pathway inhibitor (TFPI) levels and upregulating cell adhesion molecules like VCAM and ICAM, which facilitates extravasation of circulating white blood cells (212) (Figure 1H).

The hypercoagulable state of COVID-19 may be a function of the complex interplay between immune cells and endothelial cells. Early polymorphonuclear (PMN) cell activation may lead to neutrophil extracellular traps (NETs) forming via NETosis, as suggested by increased plasma NET formation in intubated patients with COVID-19 (213). Colocalization of citrullinated histone H3+ neutrophils with platelets in blood vessels suggests that NET formation is implicated in the development of microthrombi in COVID-19 patients (213) (Figure 1I). Macrophages and monocytes in which inflammasomes and pyroptosis are activated may release microparticles containing tissue factor (TF) (214, 215), a critical first step in the coagulation cascade (216). IL-6 may further enhance the release of TF from monocytes (217). Of note, while not unique to COVID-19, severe infections can also promote the development of disseminated intravascular coagulation (DIC), the mechanisms of which have been well-studied (218).

2.3.2 Acute lung injury

The lungs are among the earliest and most overtly affected organs in COVID-19 (219), with symptoms ranging from mild [and sometimes relatively asymptomatic (220, 221)] to severe hypoxemic respiratory failure requiring mechanical ventilation (222). Despite comparatively low ACE2 expression in the lung overall, type II alveolar epithelial cells (223) are preferentially targeted by SARS-CoV-2 (69). Early infection is typically characterized by viral pneumonia of varying severity (219, 224), which may progress to COVID-19-related acute respiratory distress syndrome (ARDS) (224) with a predominance of CD-3+ and CD-4+ T lymphocytes in precapillary and postcapillary blood vessels (208). As with other organ systems, the anatomic and clinical sequelae of viral infections within the lungs are related both to the infection and to the inflammatory response with which it is accompanied (225). Findings in early COVID-19 typically manifest as bilateral peripheral ground-glass opacities and consolidations, which may reflect diffuse alveolar damage when examined histologically (225). As with other viruses, organizing pneumonia can also be seen, as well as bronchiolitis, manifesting as bronchial wall thickening, centrilobular nodules, and tree-in-bud opacities (225). While early studies hypothesized a unique trajectory of lung compliance changes in COVID-19 ARDS (226), later studies suggest that COVID-19 ARDS is a heterogeneous entity composed of pathophysiologic phenotypes that may be managed similarly to previously described phenotypes of ARDS (227–231). The overlap with typical ARDS in severe COVID-19 may explain the benefit of dexamethasone in hospitalized patients with an increased supplemental oxygen requirement (232), similar to a recent trial studying dexamethasone in ARDS (233). Of note, the development of endotheliitis and microthrombi (208, 234) in COVID-19 does appear to be unique to SARS-CoV-2 as compared to other viral illnesses such as influenza H1N1 (208, 235), a finding which may reflect SARS-CoV-2 tropism for ACE2 on endothelial cells (197, 203, 205, 206) exacerbated by an inflammation-related hypercoagulable state (236). In line with such pathophysiology, the initiation of therapeutic-dose anticoagulation in non-critically ill patients has been shown to be effective in preventing the need for mechanical ventilation and improving survival to hospital discharge (237). Initiation of anticoagulation during critical illness, in contrast, has not been shown to improve survival, which may be due to the timing of microthrombi development and the momentum of the inflammation-related hypercoagulable state (238). Of note, overt pulmonary emboli (PE) have a pooled incidence of 21% in hospitalized patients with COVID-19 (239); treatment for PE in such scenarios involves standard anticoagulation.

2.3.3 Acute cardiac dysfunction

Although the phenomenon itself is probably rare (240), numerous studies have revealed associations of COVID-19 to myocarditis (197, 240–243). One US hospital administrative database study among patients hospitalized from March 2020 to January 2021 showed that the risk for myocarditis was 0.146% for patients with COVID-19 compared to 0.009%, with an estimated 15.7 times increased risk for the syndrome (244). In several such cases, SARS-CoV-2 mRNA was shown to be present in the myocardium and was associated with an intense inflammatory response comprised of macrophages and CD8+ cytotoxic T-cells (245, 246). At least one patient exhibited no overt evidence of pulmonary SARS-CoV-2 infection (245). Other mechanisms of acute cardiac involvement may include stress-related (Takutsobu) cardiomyopathy (242) and myocardial infarction (240, 247) related to supply-and-demand mismatch (248) or overt coronary occlusion (249). COVID-19-associated IL-6 production can also affect cardiac function: IL-6 has been shown to exacerbate viral myocarditis (240), and a recently submitted study using cardiac organoids stimulated with IL-1β suggests cardiac dysfunction may be due to downregulation of sarcomere components, reduced sarcomere width, contraction amplitude, increased cardiac fibrosis, and prothrombotic vasculature, irrespective of direct infection with SARS-CoV-2 (250).

2.3.4 Acute neurologic and psychiatric dysfunction

Neurological manifestations of COVID-19 appear to portend a worse outcome in terms of in-hospital mortality, hospital length of stay, and persistent functional disability (251). Neurological manifestations were estimated to occur in as many as 80% of patients hospitalized with COVID-19 (252), with the most common self-reported symptoms including headache (37%) and anosmia/ageusia (26%) and the most common syndromes including encephalopathy (49%), coma (17%) and stroke (6%) (252). Ischemic stroke appears to be more prevalent in SARS-CoV-2 infection (1.6%; 95% CI 1.1-2.3%) (253) than in influenza (0.2%; 95% CI, 0.0%-0.6%) (253, 254). COVID-19 patients with co-morbid pre-existing dementia are at exceptionally high risk for in-hospital delirium, itself associated with prolonged hospitalization, intensive care unit (ICU) admission, or in-hospital mortality (251). Other disorders include seizures, hypoxic/ischemic brain injury (251), encephalitis (255), critical illness neuropathy/myopathy, myalgias, and dizziness (251). Psychiatric disorders including psychosis (255), anxiety, depression and post-traumatic stress disorder (PTSD) were also reported in COVID-19 patients (256). Single-cell CSF analysis in patients with neurological manifestations demonstrated a dampened interferon response, an increase in de-differentiated monocyte populations, and exhausted CD4+ T-cell phenotypes (257). Other proposed mechanisms of neurological dysfunction include endothelial damage, local inflammation (258), direct effect on choroid plexus epithelium, glial cell tropism, retrograde transportation into the CNS from the olfactory bulb (256), and hypoxic-ischemic injury to the CNS (256).

2.3.5 Immunologic effects on the kidney accompanying SARS-CoV-2 infection acute kidney injury

The kidney is unique in its high concentration of ACE2, its increased vascularity, and its exposure to systemic pathogens (16). ACE2 is co-expressed with TMPRSS2 in podocytes and tubule epithelial cells as it is in the lungs (259). Furin and CD147, which bind SARS-CoV-2, are likewise expressed in the kidney (260). Immune cells in the healthy human kidney are sparse and are primarily CD4+ and CD8+ T cells, with a smaller percentage of NK cells, B cells (17), and CD14+, CD16+ and CD68+ myeloid cells (18). Infection with SARS-CoV-2, a shift occurs from an upregulation in proinflammatory genes such as HSPA1A in podocytes and JUN1 in mesenchymal clusters (19) can accompany selective immune suppression of lymphocytes mediated through T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and Programmed cell death protein 1 (PD-1) (20). A 2022 review suggests that resident immune cells may mediate inflammation by TNFα release, IL-34-mediated necrosis, and NLRP3 inflammasome production (266). ICAM-1, E- and P-selectin upregulation may be associated with neutrophil and circulating immune cell recruitment, platelet activation, NETosis (266), and immunothrombosis. While tropism for the kidney had previously been debated (255), the detection of SARS-CoV-2 RNA in a case series of kidney autopsies (264) suggests a role for direct infection. One elegant study built on the finding of increased extracellular matrix (ECM) in pathological specimens to explore an association with tubule-interstitial nephrosis (260). In this study, single-cell RNA sequencing of SARS-CoV-2-infected human-induced pluripotent stem-cell-derived kidney organoids confirmed the presence of SARS-CoV-2 in podocytes, proximal tubular cells, and myofibroblasts. Increased collagen one protein expression was seen in SARS-CoV-2 infected organoids compared to controls, a finding abrogated with a TGF-β blocker (SB431542). Moreover, the upregulation of HSPA1A, NRF21, S100A9, and TMSB10 proinflammatory genes was seen in podocytes, as was CCN1, JUN, and NFKBIA in mesenchymal clusters. Pathways upregulated among SARS-CoV-2-infected cells included TGF-β, PI3K/Akt, MAPK, and WNT signaling in proximal tubular cells and mesenchymal clusters (260). Upregulated IL-6 and STAT3 signaling may be important in COVAN-mediated disease (265). These results support a hypothesis that SARS-CoV-2 promotes tubule interstitial fibrosis through profibrotic pathways, at least in severe disease (Figure 4).

Figure 4

Of note, patients with ESRD may already exhibit exhausted T-cell phenotypes (259). As discussed above, infection with SARS-CoV-2 is likewise associated with lymphopenia and exhausted T-cell phenotypes (260), which may indicate exacerbated immune dysregulation in such patients. Patients with ESRD have been shown to produce durable antibody anti-nucleocapsid and anti-RBD antibodies at least 6 months post-infection (261, 262), although this was not found to correlate with a decreased likelihood of reinfection in patients undergoing hemodialysis (263). While not the subject of this review, a more recent study noted that patients with both mRNA-1273 vaccination as well as prior infection with SARS-CoV-2 exhibited more robust neutralizing antibody production and S-specific B-cells were higher among patients with chronic kidney disease, and that the percentage of S-specific memory CD4+ and CD8+ T-cells were higher among patients who were dialysis-dependent than healthy hybrid controls (264).

Early studies in China suggested an incidence of AKI in 4.7% of all patients presenting with SARS-CoV-2 infection by Kidney Disease: Improving Global Outcomes (KDIGO) Criteria (265, 266). In another study, AKI was reported in approximately 25% of hospitalized patients with COVID-19 (267). The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) for Severe Emerging Infections was among the largest epidemiological studies performed during the COVID-19 pandemic (268). Among the 85687 patients in this multicenter cohort, 2198 (2.6%) ultimately underwent acute renal replacement therapy (RRT) (long-term dialysis patients were excluded.) Among 41294 patients with available serum creatinine, 13000 (31.5%) had biochemical AKI: 8562 had stage 1 (65.9%), 2609 stage 2 (20.1%) and 1829 stage 3 (14.1%), with a concurrent increased risk in 28-day mortality by AKI severity (stage 1: aOR 1.58 (1.49–1.67); stage 2: aOR 2.41 (2.20–2.64); stage 3 aOR 3.50 (3.14–3.91); and RRT aOR 3.06 (2.75–3.39) (268). As summarized in the 2022 study, predominant risk factors for RRT were chronic kidney disease (CKD) (aOR 3.41; 95% CI=3.06–3.81), male sex (aOR 2.43; CI=2.18–2.71) and Black race (aOR 2.17; CI=1.79–2.63). Primary risk factors for biochemical AKI were admission respiratory rate >30 breaths per minute (aOR 1.68; CI=1.56–1.81), CKD (aOR 1.66; CI=1.57–1.76), and Black race (aOR 1.44; CI=1.28–1.61) (268).

In addition to the acute effect of COVID-19 and its consequences on the kidney, an early phenome-wide association study (PheWAS) of patients showed a significant increase in the likelihood of hospitalization among those patients with stage 4 CKD and above (Stage 4 CKD: OR 2.90, 95% CI: 1.47, 5.74), stage 5 CKD or dialysis (OR 8.83, 95% CI: 2.76, 28.27) (269). The odds of hospitalization were especially high among kidney transplant recipients (OR 14.98, 95% CI: 2.77, 80.8) (269), with plausible mechanisms including transplant rejection as seen in a 2021 biopsy series (270).

In the largest biopsy series among patients with SARS-CoV-2 infection (45.4% with AKI and 42.6% for proteinuria with or without AKI), among whom 44.6% were African American, the most common diagnosis was collapsing glomerulopathy (25.8%) (270). Of those patients, 91.7% had high-risk APOL1 genotypes (270) [G1/G1, G1/G2, or G2/G2 (271)]. Increased rates of myoglobin cast nephropathy (3.3%), proliferative glomerulonephritis with monoclonal IgG deposits (PMIG) (1.7%), and rejection among transplant patients (61.4% of transplant patients) were also seen when compared to historical controls (Figure 4A) (270). Lower rates of arterionephrosclerosis, diabetic nephropathy, and IgA nephropathy were also noted within this cohort (270). Only 3.7% of biopsy specimens within this series exhibited SARS-CoV-2 N protein by immunohistochemistry, none of which were positive by in situ hybridization (272).

The unique association of COVID-19 and collapsing glomerulopathy has led to the identification of an entity known as COVID-19 associated nephropathy (COVAN), which is thought to be similar to HIV-associated nephropathy (HIVAN) (273). Mechanisms of COVID-19-induced collapsing glomerulopathy—a variant of focal segmental glomerulosclerosis (FSGS) characterized by collapse of the glomerular capillaries with hypertrophy of the overlying podocytes (271)—may include direct infection as well as thrombotic microangiopathy or other ischemic insults (271). In addition to the above-mentioned immunologic processes, mechanisms of COVID-19-related AKI include acute tubular injury (ATI) and acute tubular necrosis (ATN) from various etiologies, including systemic hemodynamic instability (267). Proteinuria can occur in COVID-19-related AKI and is typically low molecular weight, indicative of tubular injury (267). Other proposed mechanisms include intravascular hypovolemia, increased right heart filling pressures secondary to pulmonary pathology with associated renal venous vascular congestion, rhabdomyolysis, glomerulonephritis, and collapsing glomerulopathy (267). Additional patho-etiologies include endothelial inflammation, microthrombi formation, and thrombotic microangiopathy (267). NET-related immunothrombosis may be implicated, particularly in patients with proteinuria (111). Nephrotoxic agents administered during the course of hospitalization may also cause AKI through varied mechanisms (267) (Figure 4).

2.3.6 Gastrointestinal damage and dysfunction

Up to 50% of patients with COVID-19 develop GI symptoms such as nausea, abdominal pain, and diarrhea (274). SARS-CoV-2 can be detected in the stool, suggesting a role for fecal-oral transmission (275). Enterocytes can be directly infected with SARS-CoV-2 (276). Inflammatory infiltration of the intestine comprised of neutrophils, macrophages, and lymphocytes may be seen in severe COVID-19 (276). Studies in human small intestinal organoids reveal a response similar to that seen in the lungs (277), with low levels of interferons I and III and high levels of chemokines such as IP-10 and CXCL10 (278) skewing the immune response towards inflammation with less potent antiviral activity (274, 277). Systemic inflammation, including cytokine release, can induce leakiness in the gut mucosal barrier, leading to exposure to LPS and β-D-glucan and the development of neutrophil extracellular traps (NETs) (279). Alterations in the gut microbiome in SARS-CoV-2 infection are thought to contribute to COVID-19-mediate inflammation, including through increased gut permeability and associated endotoxemia (280). In one study of metagenomic and metaproteomic profiles of COVID-19 patients, an increase in opportunistic pathogenic species such as Burkholderia contaminans was seen along with a decrease in commensal bacteria and was associated with illness severity, highlighting the role of the microbiome (281). Other studies showed increases in Escherichia coli, Klebsiella pneumoniae and Enterococcus faecalis (282). Antibiotic use during the pandemic is also likely to have contributed to microbial dysbiosis (282). The reduction in short-chain fatty acids, metabolites of a normal microbiome that can serve as fuel for enterocytes and regulators of innate and adaptive immunity, may help to explain COVID-19-related microbial dysbiosis (282).

3 Post-acute and chronic immunologic and inflammatory response to SARS-CoV-2

Early waves of the pandemic were followed by the growth of a population of patients who continued to suffer from physical and neuropsychiatric symptoms (283) as well as overt organ damage (284). In the UK’s National Health System (NHS), for instance, approximately one-third of patients who were hospitalized with COVID-19 were readmitted to the hospital within 5 months (284), implying a substantial individual and public health burden. A collection of symptoms, including shortness of breath, fatigue, memory loss, GI distress, and anosmia, has come to be called “long COVID” or post-acute sequelae of COVID-19 (PASC) (285). In a recent meta-analysis that alluded to substantial study heterogeneity (I² = 100%, P < 0.001), global pooled prevalence of any post-COVID-19 condition is estimated to be approximately 43% (95% CI, 39-46%) (283), with fatigue being the most common symptom reported (23%; 95% CI, 17-30%) and with symptoms more likely to be present in patients who were hospitalized with COVID-19 (283). Other studies reported at least one PASC symptom in half of all survivors of COVID-19, extending to at least 6 months following hospitalization (median 54.0% (IQR 31.0%-67.0%) (286). Pre-existing comorbidities likely predispose patients to PASC: A recent study showed a prevalence of 2.8% to 5.5% in people with pre-existing health conditions as compared with 1.8% in healthy controls (287). Mechanisms of post-COVID organ dysfunction and PASC are an area of current and active interest (285, 288) with definitions of PASC being in a state of flux likely accounting for the heterogeneous findings (283).

3.1 Systemic inflammatory response to COVID-19: long-term effects from acute response and long-term immune response

3.1.1 Persistent viral RNA

Pathological studies have shown that SARS-CoV-2 viral RNA can persist and replicate throughout the body in multiple organs, including the heart, lung, brain, small intestine, and adrenal gland, for at least seven months post-infection (289). Circulating spike protein has been detected in approximately 60% of patients diagnosed with PASC for up to 12 months post-infection compared to those not diagnosed with PASC (290). While the clinical implications are unclear (289), the above findings and several other studies have fueled the hypothesis that PASC may be related to viral persistence (291). The presence of antibodies to spike antigen in 60% of COVID-19 survivors with PASC, in contrast to 0% of such antibodies in patients without PASC, indirectly points to a viral reservoir promoting persistent inflammation (290, 292). Of note, although less common than with DNA viruses, the phenomenon of persistent RNA virus is not unique to SARS-CoV-2 (293, 294) and has been seen with adenovirus, enterovirus, parvovirus B19 (293, 294), rhinovirus, respiratory syncytial virus (RSV) and others, and correlated with cardiomyopathy, asthma, and chronic pulmonary disease (293). The attention to virus-associated clinicopathology that the SARS-CoV-2 pandemic has spurred may thus prove impactful for many chronic illnesses.

3.1.2 Altered immune activation with co-presentation of EBV

Among the mechanisms studied for persistent symptoms in patients who have recovered from acute COVID-19 is altered immune activation to co-persistent Epstein-Barr Virus (EBV) (291). A 2021 study found that those patients who suffered from PASC symptoms were more likely to have evidence of EBV reactivation manifesting as early antigen diffuse (EA-D) IgG or viral capsid IgM (295). A later study showed that detection of EBV DNA was more than twice as common (27.1% vs. 12.5%) in patients diagnosed with COVID-19 (296). In another study, EBV viremia was seen in 14% of patients diagnosed with acute COVID-19 (285). In that same study, EBV viremia was associated with specific symptoms of PASC such as fatigue (285). Given the association of EBV with a number of clinical conditions ranging from chronic fatigue syndrome and multiple sclerosis (297), it’s role in acute and chronic forms of COVID-19 should not be ignored. Of note, re-activation of dormant infections is likely not unique to EBV in COVID-19. Similar phenomena have been suggested with tuberculosis (298) and toxoplasmosis (299), and may yet be the subject of further study.

3.1.3 Persistent cytokine release and the role of inflammasomes

Cytokines such as IL-2, IL-6, IL-17, TNFα, and IFN-γ may be persistently elevated for weeks during active acute COVID-19 (139) and may continue to be elevated in the early post-acute phase of COVID-19 (300, 301). In particular, IL-6, IFN-β, IFN-γ, and IFN-λ2/3 are associated with symptoms of PASC at least eight months after acute infection (301). Macrophages and monocytes may be responsible for the ongoing release of IL-1β, IL-6, and TNF (302). Hypotheses about the relevance of persistently elevated cytokines in PASC include low-grade chronic peripheral inflammation leading to microglia dysfunction and neuro-inflammation, which may explain “brain fog” and similar symptoms. This mechanism has yet to be proven (303). Among the mechanisms of cytokine release, the inflammasome-mediated pyroptosis pathway has been implicated in COVID-19 (67) and may involve NLRP3 (304). NLRP3 is associated with the development of such autoimmune conditions as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory bowel disease (IBD) (305). Therefore, persistent NLRP3-mediated inflammation via IL-1β may be at play in patients with PASC (306). In a study among PASC patients with lung fibrosis, activation of the Absent in Melanoma 2 (AIM2) inflammasome was associated with the release of IL-1α, IFN-α and TGF-β, a finding not seen in non-PASC patients (306). Of note, in that same study, the provocation of NLRP3 with LPS or ATP did not induce IL-1α release (306). The significance of inflammasomes in acute and chronic forms of COVID-19 remains the subject of ongoing study (307).

3.1.4 Autoantibodies

Autoantibody development may be associated with the emergence of PASC (285). Several patients can develop autoantibodies early in the course of illness (308), as well as convalescent patients (285) (Figure 2E). Among a cohort of patients with life-threatening COVID-19, 10.2% were found to have IgG autoantibodies to type I IFNs IFN-α2 and IFN-ω (309). A unique sequencing technique called Molecular Indexing of Proteins by Self-Assembly (MIPSA) further identified type III-anti-IFN-λ3 autoantibodies in patients with severe COVID-19 (415). Another study revealed that one out of every four hospitalized patients with COVID-19 in their cohort had anti-nuclear antibodies (ANA) of various titers and patterns (308). Following acute infection, autoantibodies can linger or develop anew. In a recent study, 44% of patients with symptoms of PASC were found to have autoantibodies, including the ANAs Jo-1, Ro/SS-A, La/SS-B, U1-snRNP, P1, and anti-IFN-α2, approximately 2-3 months after initial symptom onset (285). Intriguingly, immune profiles of patients with PASC may be similar to those with SLE (285, 310). While it is difficult to ignore the possibility of pre-existing autoantibodies in certain patients before the development of COVID-19, a 2022 study points out that few of the patients found to have autoantibodies early in the course of illness had clinical evidence of autoimmune disease before COVID-19, suggesting a pre-existing subclinical autoimmune process that COVID-19 exacerbates (285).

3.1.5 T-cell and B-cell subpopulations

In the early post-recovery phase, lymphopenia may persist (300). Following acute infection, CD4+ and CD8+ T-cell populations that upregulate genes associated with inflammatory regulation are preferentially expanded, and those associated with effector functions are contracted (285). In some patients, however—particularly those experiencing GI symptoms of PASC—populations of cytotoxic CD4+ and CD8+ T-cells continue to evolve into new clones, suggesting a role for T-cell-mediated inflammation in PASC (285). Additional studies have shown that naive CD127^lowGzmB⁻CCR7⁺CD45RA⁺CD27⁺CD8⁺ T-cells, naive CD127^lowTIM-3⁻CCR7⁺CD45 RA⁺CD27⁺CD4⁺ T-cells, and naive CD127^lowTIM-3⁻CD38^lowCD27⁻IgD⁺ B cells are absent eight months post-infection in patients with PASC, suggesting ongoing activation of normally naïve T-cell and B-cell subsets (301). As noted above, T_H17 cells may be preferentially expressed in the hyperinflammatory environment in COVID-19, which includes TGF-β and IL-6 (153, 311). T_H17 cells have been associated with several autoimmune diseases, including asthma, multiple sclerosis, SLE, and RA (153). Specific cell signatures in T-cells, B-cells, and NK cells have defined different immune endophenotypes among patients with PASC (285). The interplay between T-cells and other viruses in a patient’s virome (312), such as EBV and CMV, may also affect the development of PASC symptoms (285). Additional research can help further describe clinical and endophenotypes following infection with SARS-CoV-2 and elucidate the significance of these findings.

3.2 Post-acute and delayed inflammation-related end-organ injury following SARS-CoV-2 infection

3.2.1 Multisystem inflammatory syndrome in children and adults (MIS-C; MIS-A)

Multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) are distinct acute hyperinflammatory illnesses involving end-organ dysfunction (313) that can occur 2-12 weeks after acute infection with SARS-CoV-2 (314). Diagnostic criteria for MIS-C vary but typically include age <21 years, persistent fever, involvement of ≥2 organ systems [e.g., cardiac dysfunction (seen in 86.5% in one study), dermatologic or mucocutaneous involvement (70.9%), and GI involvement (90.9%) (315)] and inflammatory markers in the context of a preceding SARS-CoV-2 infection (313). Diagnostic criteria for MIS-A presently include severe cardiac illness, dermatologic and conjunctival manifestations, and elevated inflammatory markers in the context of recently positive SARS-CoV-2 PCR, antigen, or antibody testing in patients >21 (316). It is important to note that these two syndromes, while similar in name, likely reflect distinct pathological processes. MIS-C is more common than MIS-A and exhibits strong similarities to Kawasaki Disease (313). Both MIS-C and MIS-A exhibit similarities to macrophage activation syndrome (MAS), secondary hemophagocytic lymphohistiocytosis (HLH), and toxic shock syndrome (317) and may be equivalent to an immunologic aftershock following a sometimes-benign initial infection (317). MIS-C may be distinguishable from severe COVID-19 by cytokine profile differences such as increased IL-10 in MIS-C (317). Coronary artery aneurysms have been reported in MIS-C (318); both MIS-C and MIS-A can be associated with myocarditis (319–321), which can progress to cardiogenic shock (321) and may respond to immunosuppressive agents (13, 320, 321).

3.3 Chronic end-organ dysfunction following infection with SARS-CoV-2

The early effects of SARS-CoV-2 infection and the associated immune response can have a long-term impact on multiple organ systems. Post-acute sequelae of COVID-19 (PASC), also called Long COVID, long-haul COVID, and other names, is now widely recognized as a clinical entity carrying its own International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis (U09.9 Post COVID-19 condition, unspecified) (322). The convenience of a unifying diagnostic code belies the sundry manifestations of this condition. Patients who have recovered from COVID-19 may display clinical and pathological evidence of end-organ dysfunction, which may overlap those underlying PASC (Figure 3B). Pre-existing factors such as older age, female gender, higher BMI, and previous hospitalization are associated with the development of symptoms of PASC (323).

3.3.1 Cardiac dysfunction

A large US Veterans’ study found that the risk of cardiovascular disease, including inflammatory heart disease, was increased beyond 30 days after acute SARS-CoV-2 infection, even when mild (324). COVID-19 in the acute phase (defined as ≤ 21 days) and in the post-acute phase (> 21 days) were shown to be associated with an increased risk of cardiovascular disease than contemporary controls [hazard ratio (HR) for acute phase: 4.3 (CI=2.6-6.9); HR for post-acute phase: 1.4 (CI=1.2-1.8)], findings which also held for historical controls whose population health was not overtly impacted by COVID-19 as a whole (325, 326). The risk of ischemic heart disease, heart failure, myocardial infarction, MACE, myocarditis, and pericarditis were all increased in the 12 months following acute SARS-CoV-2 infection (324). The risks of atrial fibrillation, ventricular arrhythmias, and other dysrhythmias were also higher (324). Myocarditis carried the highest risk (HR 5.38; CI: 3.80-7.59) of all such outcomes, which remained increased for COVID-19 patients even when vaccination was accounted for (324). A retrospective cohort study from a US health plan reported similarly increased risks in several of the outcomes mentioned above, as well as an increase in the diagnosis of hypertension (327). The risk of cerebrovascular disorders like stroke and TIA was also increased (324). While the impact of pre-existing comorbidities should not be ignored (287), subgroup analyses of the 2022 Veteran study suggested that COVID-19 was itself a risk factor for future cardiovascular disease regardless of pre-COVID-19 risk (324, 328). Moreover, COVID-19 disrupted the care of patients with cardiovascular disease and was associated with an overall increase in mortality due to these conditions (326).

3.3.2 Pulmonary dysfunction

Pulmonary hypertension (and associated right-sided cardiac dysfunction) (329) can be observed as a result of pulmonary fibrosis (330) and prior pulmonary emboli (i.e., Group 3 and Group 4 pulmonary hypertension, respectively) (331). Patients with pulmonary emboli may exhibit functional limitations and dyspnea (332) even in the absence of overt pulmonary hypertension. Notably, the risk of new-onset PE [as defined by hazard ratio (HR) (324)] and a new diagnosis of pulmonary hypertension (327) have also been found to be higher in patients who have had COVID-19. On imaging, early infection with SARS-CoV-2 can give way to air trapping in patients with PASC seen in a post-COVID-19 clinic 42-204 days after diagnosis (333). This CT finding suggests persistent small airway disease (333), presumably reflective of post-viral constrictive bronchiolitis, and is typically not associated with large airway obstruction on pulmonary function tests (PFTs) (333, 334). Patients with more severe infections (i.e., those requiring an ICU stay) were additionally found to have GGOs, architectural distortion, honeycombing, scar, or traction bronchiectasis accompanied by restrictive lung physiology and a reduction in DLCO (333, 335). Pulmonary fibrosis and interstitial lung disease (ILD) following COVID-19 (336–338) may be due to an initial hyperproliferation of pathologic fibroblasts acting via TGF-β signaling (339). Post-COVID pulmonary complications are likely to be related to disease severity, as suggested by an association with the inflammatory markers ESR and CRP (340), as well as to pre-existing comorbidities (287). Observational studies are now underway to elucidate the mechanisms and clinical trajectory of post-COVID-19 ILD (336). The risk of a new diagnosis of sleep apnea appears to be higher following hospitalization for COVID-19 (327).

3.3.3 Neuropsychiatric symptoms

Neuropsychiatric symptoms can be a prominent component of PASC and are typically characterized by fatigue, cognitive dysfunction, and post-exertional malaise (341). A recent survey study confirmed similarities between fibromyalgia and chronic fatigue syndrome with respect to self-reported fatigue, cognitive function, anxiety, depression, kinesiophobia, pain, and physical dysfunction, although patients with PASC had lower levels of fatigue and pain (342). Neurocognitive testing confirmed impairments in 46% of this preselected group of patients (343) and has been reported in other populations (344). Persistent neuroinflammation and endothelial injury are among the proposed mechanisms for this phenomenon (345).

Laboratory abnormalities among patients with PASC include reduced cortisol levels (346) and a reduced circulating serotonin level (347). A compensatory increase in ACTH was not seen among patients with low cortisol, which may reflect a blunted stress response in patients with PASC (346). The correlation between viral-RNA-induced type I interferons and reduced serotonin is thought to be mediated by reduced tryptophan uptake and storage and hypercoagulability, as shown in a recent elegant study from 2023 (347). In that same study—which opened the door to a compelling mechanism underlying PASC—cognitive dysfunction correlated with peripheral serotonin depletion (347).

In post-hospital discharge patients with symptoms of PASC, the most common MRI finding was scattered white matter lesions (343). An increased risk of incident ischemic and hemorrhagic stroke, encephalitis, encephalopathy, migraine, seizures, sensory disorders, peripheral nervous system disorders, musculoskeletal disorders, Guillain-Barre Syndrome, and extrapyramidal disorders was seen among patients followed for 12 months following acute SARS-CoV-2 infection, with an estimated HR for any neurologic sequela of 1.42 (1.38-1.47) (344). In one comprehensive NIH study of 12 patients with neurologic sequelae of SARS-CoV-2 infection, mild cognitive impairment (Montreal Cognitive Assessment Score (MoCA) < 26) was seen in half of the patients, with deficits predominantly seen in short-term memory (348). No MRI abnormalities were seen in those patients. Immunophenotyping of CSF revealed higher frequencies of antibody-secreting B cells and PD-L1-expressing monocytes and lower frequencies of CD4+ and CD8+ effector memory cells (348). It should be noted that one-third of patients included in the study had a prior history of resolved long-term disability due to a preceding infection (amoebiasis due to Entamoeba histolytica, infectious mononucleosis, Lyme disease, and severe sepsis due to group A Streptococcus) (348).

3.3.4 Persistent renal dysfunction and chronic kidney disease

In a US health plan cohort, renal dysfunction, as defined by a composite of AKI and CKD, was found to be more likely after a diagnosis of COVID-19 in hospitalized patients with a pre-existing condition (327). Other studies reported an increased likelihood of a new diagnosis of CKD within the first 4-6 months following COVID-19 in addition to AKI (284, 349). A large VA health system study also revealed an increase in the diagnosis of CKD following COVID-19 infection in hospitalized and intensive care unit patients (HR, hospitalized patients=1.36 (CI=1.24-1.49), and HR for ICU patients=1.88 (1.66-2.13) (350).

CKD is known to be associated with altered immunity. ESRD has likewise been defined in part as a state of “acquired immunodeficiency” by Vanholder and Ringoir in 1993 (351), although simultaneously heightened levels of inflammation and immune activation have also been described noted (352). In ESRD patients, CD14+CD16+ monocyte populations are expanded, cytokine production and chemokine expression is increased, as is basal ROS production (352, 353). LDL likewise elicits a stronger pro-inflammatory response (354). In contrast, a decreased number of DCs with impaired function (355) are seen, circulating PMNs have decreased phagocytic capacity, naïve and central memory T cells are depleted (with a reduced CD4+/CD8+ T cell ratio), CD4+CD25bright+FoxP3+ Treg populations are both diminished and impaired, and B cell populations are likewise diminished (352).

An early PheWAS study cited above pointed to a strong association between pre-existing Stage 4 CKD, Stage 5 CKD, and dialysis with the likelihood of hospitalization with even higher odds among kidney transplant recipients , suggesting a disproportionate impact among those with pre-existing renal disease as well as the bidirectional interplay between COVID-19 and CKD (356). Among 758 patients in the Health Outcome Predictive Evaluation of COVID-19 (HOPE COVID-19) Study, an eGFR of < 60 ml/min/1.73m² was associated with a higher risk of in-hospital mortality (eGFR > 60: 18.4%; eGFR 30-60: 56.5%; and eGFR < 30: 65.5%; p < 0.001), multi-organ failure, and sepsis (356, 357). Notably, while only 8.5% of the HOPE-COVID-19 cohort had documented CKD on admission, 30.6% (N=322) presented with eGFR < 60 ml/min/1.73m², suggesting a role in the development of AKI as described above (356, 357).

Mechanisms of the development of CKD in the general population include the progression of changes set in motion through COVID-19 AKI, particularly as the development of AKI itself can be associated with the eventual development of CKD (358). Acknowledging the unique etiological mechanisms of the initial AKI insult (359, 360), injury of proximal tubule cells in severe AKI may result in cell cycle arrest in the G2/M phase, which leads to the secretion of TGF-β and connective tissue growth factor, both of which mediate fibrosis through c-jun NH2-terminal kinase (JNK) signaling (359, 361). Following AKI, animal models have shown that aberrant activation of developmental pathways such as Hedgehog and Wnt/β-catenin can also promote fibrosis (359). Persistent mitochondrial dysfunction following the initial insult may also play a role in developing fibrosis and persistent inflammation (359). Resident P0-Cre fibroblasts in the renal cortex and medulla (359) may transdifferentiate into αSMA-positive myofibroblasts and promote fibrosis (359); Gli1-Cre fibroblasts are likewise related to end-organ fibrosis and may be therapeutically targeted (362).

A 2022 study reviewed a biopsy series and confirmed the presence of tubule interstitial fibrosis in patients with COVID-19 as compared to age, sex, and comorbidity-matched controls ; in an elegant study described above for AKI, infection of human iPSC-derived organoids elucidated SARS-CoV-2-specific pathways of tubule-interstitial fibrosis mediated through direct infection (19). Early pro-inflammatory, fibroblast activation, and myofibroblast differentiation, including those mediated by TGF-β, NFκB, and JAK-STAT, were upregulated in podocytes, proximal tubule cells (PTC), and fibroblasts, with a concomitant increase in ECM and collagen deposition (19). Additional mechanisms are described above. Further, the initial binding of SARS-CoV-2 with ACE2 in the kidney in acute infection limits its bioavailability for Ang1-7 production, leading to fibrosis (363) and maladaptive repair (359, 364). Mechanisms in immunocompromised patients may involve direct damage to podocytes and proximal convoluted tubules via SARS-CoV-2 colocalization with Le^x and sialyl-Le^x (CD15s) in addition to ACE2 in the setting of chronic replication of SARS-CoV-2 as seen on biopsy from a patient with splenic marginal cell lymphoma (365).

Much of the research on COVID-19 AKI and CKD has been performed among patients with more severe illness. A 2022 study of a primarily ambulatory cohort of patients in Hamburg, Germany, showed a decreased eGFR (regression estimate -2.35mL/min/1.73m² (CI= -4.28, -0.42); Bonferroni adjusted p=0.019) as compared to matched controls (366). Mechanisms or histological specimens were not described in this study. However, it is conceivable that SARS-CoV-2-mediated AKI and subsequent CKD exist on a spectrum, and likely that if so, the above mechanisms are at play in what may be considered “renal PASC.” As noted above, persistent viral RNA may be among the mechanisms in renal PASC (291).

3.3.5 Other organ systems

In a large cohort of post-discharge patients in the UK’s NHS, the rate of new diagnoses of chronic liver disease increased following hospitalization for COVID-19 (284). Diagnosis of diabetes was also increased (284). A large VA cohort identified an excess burden of diabetes beyond thirty days after COVID-19 diagnosis in non-hospitalized patients, in addition to lipid disorders and obesity (350). An increased burden of esophageal disorders, gastrointestinal disorders, and dysphagia was also seen, as was incident elevated alanine aminotransferase (ALT) levels (350). As described above in the context of acute infection, mechanisms of excess inflammation in post-infectious symptoms include alterations in the gut microbiome, with acute and post-infectious inflammation possibly reflecting perturbations in the gastrointestinal mucosal barrier (367). An extra burden of skin disorders, arthralgias, and arthritis was also seen in the VA cohort (350). Thyrotoxicosis related to both subacute thyroiditis and Graves’ Disease has been reported (368). Reports of hormonal changes in male and female patients vary; an increase in menstrual cycle has been reported (368, 369). Orchitis and epidydimo-orchitis may occur in acute COVID-19 (368). The immunologic changes that accompany SARS-CoV-2 may also prove to be associated with long-term pathophysiology in bone (370). Finally, vasculitis (371), myositis (371, 372), and rhabdomyolysis (371) have been reported in acute COVID-19; arthritis (350), including inflammatory arthritis (371), has been reported in the post-infectious period. A comprehensive summary of the end-organ effects on various organ systems affected in both acute and post-infectious COVID-19 is shown in Table 3 and Figure 3.

4 The impact of SARS-CoV-2 variants

The impact of variants throughout the pandemic is a subject of ongoing interest, particularly concerning ongoing vaccine development (373). Mutations in the S protein are likely to be the most important in determining viral tropism, infectivity, and mortality (374). However, mutations in other proteins, such as R203K and G204R in N, may also impact viral fitness (375). A 2022 study compared the impact of Delta and Omicron SARS-CoV-2 variants in a cohort of 65 patients admitted to an intensive care unit. A higher mortality rate was seen with Omicron (52.9% vs. 41.9% with Delta), although the study acknowledges a higher rate of comorbidities among Omicron patients (376). Similar PaO2/FiO2 ratios (partial pressure of oxygen in arteries to the fraction of inspired oxygen) were seen [Omicron: 156.57, SD 65.98 vs. Delta: 157.31, SD 84.56 (p=0.971)], suggesting a role for extrapulmonary pathophysiology. Organ-specific sequelae may also relate to SARS-CoV-2 variants: Cardiovascular mortality was higher during the pandemic period, ranging from March to June 2020 (likely the D614G variant) and during the Delta wave (June to December 2021) (326). Rates of AKI were higher among Omicron patients than Delta (13 (38.24%) vs. 3 (9.7%), OR 5.78; CI 1.46–22.9, p=0.0172) (376), which may be due to a higher rate of comorbidities among Omicron patients admitted to the ICU rather than being reflective of virus-specific effects.

One meta-analysis examined the impact of variants on post-COVID symptomatology by pooled estimates of several studies, reporting CT abnormalities (60.5%; 95% CI: 40.4-80.6%) and sleep difficulty (24.5%; 95%: 17.5-31.5%) to be the most common PASC symptom following infection with wild-type SARS-CoV-2, fatigue most common among survivors of the Alpha variant, and myalgia among survivors of the Omicron variant (11.7% (95% CI: 8.3-15.1%) in Omicron compared to 9.4% (95% CI: 6.3-12.5%) in wild-type) (377). In that same study, the Alpha and Gamma variants had higher rates of dyspnea (34.2% (8.3-60.1%) and 43.0% (35.3, 50.8%), respectively). The Alpha variant was found to have a higher rate of patients with greater than one general symptom of PASC and fatigue (377). As noted by the authors and as suggested by recent meta-analyses, vaccination is likely to have attenuated the risk of PASC among survivors of COVID-19 (323, 378, 379). As pointed out by the authors of a recent study on pooled survivors of COVID-19 across SARS-CoV-2 variants (323), however, it is difficult to parse out the interaction of vaccines with individual variants, which may be the subject of future studies.

Mechanisms underlying responses to variants of concern may vary. Studies in zebrafish models showed that the wild-type (WT)/Wuhan SARS-CoV-2 variant activated emergency myelopoiesis and recruited neutrophils and macrophages through inflammasome production (380). Deficiency of ACE2 led to exacerbation of inflammation, which was reversed with Ang 1-7 injection, suggesting a role for this pathway in WT-SARS-CoV-2 (380). S1 from the Gamma (P.1) variant (S1γ) and from the Beta variant (S1β from B.1.351) produced higher levels of inflammation, and S1δ (Delta variant; B.1.617.2) produced lower levels of inflammation as measured by macrophage and neutrophil recruitment as well as NF-κB activity in this study (380). A study published in November 2021 showed evidence of microvascular dysfunction among patients infected with SARS-CoV-2 (exact variants unknown) (381), which was not seen in a follow-up study among patients infected with Omicron (382). A complete discussion regarding variant-specific mechanisms of virulence is outside of the scope of this review and will likely be the subject of ongoing study [see, e.g. (375)].

5 Conclusions

In conclusion, the immune response to novel SARS-CoV-2 involves a complex milieu of cytokines, macrophages, lymphocytes, and other immune cells skewed towards a pathologically hyperactivated response. Organized but immunostimulatory pyroptosis and inflammasome production may be at play in an environment that lacks crucial early antiviral interferon production, which, along with the development of immune-mediated microthrombi, may be associated with the severity of disease in COVID-19. In the kidney, these mechanisms, as well as acute tubular injury, early myofibroblast activation, and collapsing glomerulopathy in select populations, are likely to account for COVID-19-related AKI and CKD development.

Among the limitations of this review is a thorough discussion regarding variant-specific mechanisms of immune responses, particularly as subsequent waves of the pandemic met longitudinal populations of varying degrees of immunity mediated through vaccination and natural infection. Typical immune responses to SARS-CoV-2 continue to change as the novelty of the virus changes.

It is still unclear whether the acute and long-term sequelae and associated pathophysiology following SARS-CoV-2 infection are unique to the virus or whether this reflects the unprecedented focus of research brought about by the pandemic. In any case, the pace of research in the COVID-19 era has led to a greater understanding of the components of a regulated immune response to SARS-CoV-2 and perhaps to viral infections more generally.

References

• 1

  Cucinotta D Vanelli M . WHO declares COVID-19 a pandemic. Acta Biomed. (2020) 91:157–60. doi: 10.23750/abm.v91i1.9397

  • CrossRef
  • Google Scholar

• 2

  Mather N . How we accelerated clinical trials in the age of coronavirus. Nature. (2020) 584:326. doi: 10.1038/d41586-020-02416-z

  • CrossRef
  • Google Scholar

• 3

  Wu Z Harrich D Li Z Hu D Li D . The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus. Rev Med Virol. (2021) 31:e2171. doi: 10.1002/rmv.2171

  • CrossRef
  • Google Scholar

• 4

  Ji P Zhu J Zhong Z Li H Pang J Li B et al . Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Med (Baltimore). (2020) 99:e23315. doi: 10.1097/MD.0000000000023315

  • CrossRef
  • Google Scholar

• 5

  Perico L Benigni A Casiraghi F Ng LFP Renia L Remuzzi G . Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. (2021) 17:46–64. doi: 10.1038/s41581-020-00357-4

  • CrossRef
  • Google Scholar

• 6

  Polack FP Thomas SJ Kitchin N Absalon J Gurtman A Lockhart S et al . Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577

  • CrossRef
  • Google Scholar

• 7

  Anderson EJ Rouphael NG Widge AT Jackson LA Roberts PC Makhene M et al . Safety and immunogenicity of SARS-coV-2 mRNA-1273 vaccine in older adults. N Engl J Med. (2020) 383:2427–38. doi: 10.1056/NEJMoa2028436

  • CrossRef
  • Google Scholar

• 8

  Taylor PC Adams AC Hufford MM de la Torre I Winthrop K Gottlieb RL . Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. (2021) 21:382–93. doi: 10.1038/s41577-021-00542-x

  • CrossRef
  • Google Scholar

• 9

  Owen DR Allerton CMN Anderson AS Aschenbrenner L Avery M Berritt S et al . An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. (2021) 374:1586–93. doi: 10.1126/science.abl4784

  • CrossRef
  • Google Scholar

• 10

  Jayk Bernal A Gomes da Silva MM Musungaie DB Kovalchuk E Gonzalez A Delos Reyes V et al . Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. (2022) 386:509–20. doi: 10.1056/NEJMoa2116044

  • CrossRef
  • Google Scholar

• 11

  Aldawas A Ishfaq M . COVID-19: multisystem inflammatory syndrome in children (MIS-C). Cureus. (2022) 14:e21064. doi: 10.7759/cureus.21064

  • CrossRef
  • Google Scholar

• 12

  Kashyap H Kumar RNS Gautam S Gupta A Gupta S Tiwari PK . Multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 infection. Indian J Pediatr. (2021) 88:1053. doi: 10.1007/s12098-021-03832-3

  • CrossRef
  • Google Scholar

• 13

  Cattaneo P Volpe A Cardellino CS Riccardi N Bertoli G Ursini T et al . Multisystem inflammatory syndrome in an adult (MIS-A) successfully treated with anakinra and glucocorticoids. Microorganisms. (2021) 9:1393. doi: 10.3390/microorganisms9071393

  • CrossRef
  • Google Scholar

• 14

  Patel P DeCuir J Abrams J Campbell AP Godfred-Cato S Belay ED . Clinical characteristics of multisystem inflammatory syndrome in adults: A systematic review. JAMA Netw Open. (2021) 4:e2126456. doi: 10.1001/jamanetworkopen.2021.26456

  • CrossRef
  • Google Scholar

• 15

  Gracia-Ramos AE Martin-Nares E Hernandez-Molina G . New onset of autoimmune diseases following COVID-19 diagnosis. Cells. (2021) 10:3592. doi: 10.3390/cells10123592

  • CrossRef
  • Google Scholar

• 16

  Diao B Wang C Wang R Feng Z Zhang J Yang H et al . Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun. (2021) 12:2506. doi: 10.1038/s41467-021-22781-1

  • CrossRef
  • Google Scholar

• 17

  McEvoy CM Murphy JM Zhang L Clotet-Freixas S Mathews JA An J et al . Single-cell profiling of healthy human kidney reveals features of sex-based transcriptional programs and tissue-specific immunity. Nat Commun. (2022) 13:7634. doi: 10.1038/s41467-022-35297-z

  • CrossRef
  • Google Scholar

• 18

  Park JG Na M Kim MG Park SH Lee HJ Kim DK et al . Immune cell composition in normal human kidneys. Sci Rep. (2020) 10:15678. doi: 10.1038/s41598-020-72821-x

  • CrossRef
  • Google Scholar

• 19

  Jansen J Reimer KC Nagai JS Varghese FS Overheul GJ de Beer M et al . SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell. (2022) 29:217–31.e8. doi: 10.1016/j.stem.2021.12.010

  • CrossRef
  • Google Scholar

• 20

  Wu H He P Ren Y Xiao S Wang W Liu Z et al . Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation. Nat Commun. (2022) 13:269. doi: 10.1038/s41467-021-27723-5

  • CrossRef
  • Google Scholar

• 21

  Qin G Liu S Yang L Yu W Zhang Y . Myeloid cells in COVID-19 microenvironment. Signal Transduct Target Ther. (2021) 6:372. doi: 10.1038/s41392-021-00792-0

  • CrossRef
  • Google Scholar

• 22

  Cui J Li F Shi ZL . Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. (2019) 17:181–92. doi: 10.1038/s41579-018-0118-9

  • CrossRef
  • Google Scholar

• 23

  V’Kovski P Kratzel A Steiner S Stalder H Thiel V . Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. (2021) 19:155–70. doi: 10.1038/s41579-020-00468-6

  • CrossRef
  • Google Scholar

• 24

  Hawks SA Prussin AJ 2nd Kuchinsky SC Pan J Marr LC Duggal NK . Infectious SARS-coV-2 is emitted in aerosol particles. mBio. (2021) 12:e0252721. doi: 10.1128/mBio.02527-21

  • CrossRef
  • Google Scholar

• 25

  Richard M Kok A de Meulder D Bestebroer TM Lamers MM Okba NMA et al . SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat Commun. (2020) 11:3496. doi: 10.1038/s41467-020-17367-2

  • CrossRef
  • Google Scholar

• 26

  Azimi P Keshavarz Z Cedeno Laurent JG Stephens B Allen JG . Mechanistic transmission modeling of COVID-19 on the Diamond Princess cruise ship demonstrates the importance of aerosol transmission. Proc Natl Acad Sci U S A. (2021) 118:e2015482118. doi: 10.1073/pnas.2015482118

  • CrossRef
  • Google Scholar

• 27

  Ziegler CGK Allon SJ Nyquist SK Mbano IM Miao VN Tzouanas CN et al . SARS-coV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. (2020) 181:1016–35 e19. doi: 10.1016/j.cell.2020.04.035

  • CrossRef
  • Google Scholar

• 28

  Tay MZ Poh CM Renia L MacAry PA Ng LFP . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. (2020) 20:363–74. doi: 10.1038/s41577-020-0311-8

  • CrossRef
  • Google Scholar

• 29

  Senapati S Banerjee P Bhagavatula S Kushwaha PP Kumar S . Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19. J Genet. (2021) 100:12. doi: 10.1007/s12041-021-01262-w

  • CrossRef
  • Google Scholar

• 30

  Horowitz JE Kosmicki JA Damask A Sharma D Roberts GHL Justice AE et al . Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat Genet. (2022) 54:382–92. doi: 10.1038/s41588-021-01006-7

  • CrossRef
  • Google Scholar

• 31

  Karlsen TH . Understanding COVID-19 through genome-wide association studies. Nat Genet. (2022) 54:368–9. doi: 10.1038/s41588-021-00985-x

  • CrossRef
  • Google Scholar

• 32

  Scheen AJ . DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. Diabetes Metab. (2021) 47:101213. doi: 10.1016/j.diabet.2020.11.005

  • CrossRef
  • Google Scholar

• 33

  Eleftheriou P Amanatidou D Petrou A Geronikaki A . In silico evaluation of the effectivity of approved protease inhibitors against the main protease of the novel SARS-coV-2 virus. Molecules. (2020) 25:2529. doi: 10.3390/molecules25112529

  • CrossRef
  • Google Scholar

• 34

  Letko M Marzi A Munster V . Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. (2020) 5:562–9. doi: 10.1038/s41564-020-0688-y

  • CrossRef
  • Google Scholar

• 35

  Xiong Y Delic D Zeng S Chen X Chu C Hasan AA et al . Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy-effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker. BMC Nephrol. (2022) 23:117. doi: 10.1186/s12882-022-02747-1

  • CrossRef
  • Google Scholar

• 36

  Xi CR Di Fazio A Nadvi NA Patel K Xiang MSW Zhang HE et al . A novel purification procedure for active recombinant human DPP4 and the inability of DPP4 to bind SARS-coV-2. Molecules. (2020) 25:5392. doi: 10.3390/molecules25225392

  • CrossRef
  • Google Scholar

• 37

  Reis CA Tauber R Blanchard V . Glycosylation is a key in SARS-CoV-2 infection. J Mol Med (Berl). (2021) 99:1023–31. doi: 10.1007/s00109-021-02092-0

  • CrossRef
  • Google Scholar

• 38

  Lamers MM Haagmans BL . SARS-coV-2 pathogenesis. Nat Rev Microbiol. (2022) 20:270–84. doi: 10.1038/s41579-022-00713-0

  • CrossRef
  • Google Scholar

• 39

  Jacobs JL Bain W Naqvi A Staines B Castanha PMS Yang H et al . Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes. Clin Infect Dis. (2022) 74:1525–33. doi: 10.1093/cid/ciab686

  • CrossRef
  • Google Scholar

• 40

  Markov PV Ghafari M Beer M Lythgoe K Simmonds P Stilianakis NI et al . The evolution of SARS-coV-2. Nat Rev Microbiol. (2023) 21:361–79. doi: 10.1038/s41579-023-00878-2

  • CrossRef
  • Google Scholar

• 41

  Schiuma G Beltrami S Bortolotti D Rizzo S Rizzo R . Innate immune response in SARS-coV-2 infection. Microorganisms. (2022) 10:501. doi: 10.3390/microorganisms10030501

  • CrossRef
  • Google Scholar

• 42

  Lowery SA Sariol A Perlman S . Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe. (2021) 29:1052–62. doi: 10.1016/j.chom.2021.05.004

  • CrossRef
  • Google Scholar

• 43

  Choi H Shin EC . Roles of type I and III interferons in COVID-19. Yonsei Med J. (2021) 62:381–90. doi: 10.3349/ymj.2021.62.5.381

  • CrossRef
  • Google Scholar

• 44

  Iwasaki A . A virological view of innate immune recognition. Annu Rev Microbiol. (2012) 66:177–96. doi: 10.1146/annurev-micro-092611-150203

  • CrossRef
  • Google Scholar

• 45

  Thompson MR Kaminski JJ Kurt-Jones EA Fitzgerald KA . Pattern recognition receptors and the innate immune response to viral infection. Viruses. (2011) 3:920–40. doi: 10.3390/v3060920

  • CrossRef
  • Google Scholar

• 46

  van der Made CI Simons A Schuurs-Hoeijmakers J van den Heuvel G Mantere T Kersten S et al . Presence of genetic variants among young men with severe COVID-19. JAMA. (2020) 324:663–73. doi: 10.1001/jama.2020.13719

  • CrossRef
  • Google Scholar

• 47

  Akamatsu MA de Castro JT Takano CY Ho PL . Off balance: Interferons in COVID-19 lung infections. EBioMedicine. (2021) 73:103642. doi: 10.1016/j.ebiom.2021.103642

  • CrossRef
  • Google Scholar

• 48

  Gilliet M Cao W Liu YJ . Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. (2008) 8:594–606. doi: 10.1038/nri2358

  • CrossRef
  • Google Scholar

• 49

  Bortolotti D Gentili V Rizzo S Schiuma G Beltrami S Strazzabosco G et al . TLR3 and TLR7 RNA sensor activation during SARS-coV-2 infection. Microorganisms. (2021) 9:1820. doi: 10.3390/microorganisms9091820

  • CrossRef
  • Google Scholar

• 50

  Vabret N Britton GJ Gruber C Hegde S Kim J Kuksin M et al . Immunology of COVID-19: current state of the science. Immunity. (2020) 52:910–41. doi: 10.1016/j.immuni.2020.05.002

  • CrossRef
  • Google Scholar

• 51

  Yu M Zhou H Zhao J Xiao N Roychowdhury S Schmitt D et al . MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. J Exp Med. (2014) 211:887–907. doi: 10.1084/jem.20131314

  • CrossRef
  • Google Scholar

• 52

  Goel S Saheb Sharif-Askari F Saheb Sharif Askari N Madkhana B Alwaa AM Mahboub B et al . SARS-coV-2 switches ‘on’ MAPK and NFkappaB signaling via the reduction of nuclear DUSP1 and DUSP5 expression. Front Pharmacol. (2021) 12:631879. doi: 10.3389/fphar.2021.631879

  • CrossRef
  • Google Scholar

• 53

  Li S Zhang Y Guan Z Li H Ye M Chen X et al . SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther. (2020) 5:235. doi: 10.1038/s41392-020-00334-0

  • CrossRef
  • Google Scholar

• 54

  Nainu F Shiratsuchi A Nakanishi Y . Induction of apoptosis and subsequent phagocytosis of virus-infected cells as an antiviral mechanism. Front Immunol. (2017) 8:1220. doi: 10.3389/fimmu.2017.01220

  • CrossRef
  • Google Scholar

• 55

  Ren Y Wang A Fang Y Shu T Wu D Wang C et al . SARS-coV-2 membrane glycoprotein M triggers apoptosis with the assistance of nucleocapsid protein N in cells. Front Cell Infect Microbiol. (2021) 11:706252. doi: 10.3389/fcimb.2021.706252

  • CrossRef
  • Google Scholar

• 56

  Toldo S Bussani R Nuzzi V Bonaventura A Mauro AG Cannatà A et al . Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm Res. (2021) 70:7–10. doi: 10.1007/s00011-020-01413-2

  • CrossRef
  • Google Scholar

• 57

  Bittner ZA Schrader M George SE Amann R . Pyroptosis and its role in SARS-coV-2 infection. Cells. (2022) 11:1717. doi: 10.3390/cells11101717

  • CrossRef
  • Google Scholar

• 58

  Sun X Liu Y Huang Z Xu W Hu W Yi L et al . SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. (2022) 29:1240–54. doi: 10.1038/s41418-021-00916-7

  • CrossRef
  • Google Scholar

• 59

  Hu G Christman JW . Editorial: alveolar macrophages in lung inflammation and resolution. Front Immunol. (2019) 10:2275. doi: 10.3389/fimmu.2019.02275

  • CrossRef
  • Google Scholar

• 60

  Barros-Martins J Forster R Bosnjak B . NK cell dysfunction in severe COVID-19: TGF-beta-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity. Signal Transduct Target Ther. (2022) 7:32. doi: 10.1038/s41392-022-00892-5

  • CrossRef
  • Google Scholar

• 61

  El-Arif G Khazaal S Farhat A Harb J Annweiler C Wu Y et al . Angiotensin II type I receptor (AT1R): the gate towards COVID-19-associated diseases. Molecules. (2022) 27:2048. doi: 10.3390/molecules27072048

  • CrossRef
  • Google Scholar

• 62

  Knyazev E Nersisyan S Tonevitsky A . Endocytosis and transcytosis of SARS-coV-2 across the intestinal epithelium and other tissue barriers. Front Immunol. (2021) 12:636966. doi: 10.3389/fimmu.2021.636966

  • CrossRef
  • Google Scholar

• 63

  Hojyo S Uchida M Tanaka K Hasebe R Tanaka Y Murakami M et al . How COVID-19 induces cytokine storm with high mortality. Inflammation Regen. (2020) 40:37. doi: 10.1186/s41232-020-00146-3

  • CrossRef
  • Google Scholar

• 64

  Liu T Zhang L Joo D Sun SC . NF-kappaB signaling in inflammation. Signal Transduct Target Ther. (2017) 2:17023. doi: 10.1038/sigtrans.2017.23

  • CrossRef
  • Google Scholar

• 65

  Attiq A Yao LJ Afzal S Khan MA . The triumvirate of NF-kappaB, inflammation and cytokine storm in COVID-19. Int Immunopharmacol. (2021) 101:108255.

  • Google Scholar

• 66

  Cheng DS Han W Chen SM Sherrill TP Chont M Park GY et al . Airway epithelium controls lung inflammation and injury through the NF-kappa B pathway. J Immunol. (2007) 178:6504–13. doi: 10.4049/jimmunol.178.10.6504

  • CrossRef
  • Google Scholar

• 67

  Ferreira AC Soares VC de Azevedo-Quintanilha IG Dias S Fintelman-Rodrigues N Sacramento CQ et al . SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discovery. (2021) 7:43. doi: 10.1038/s41420-021-00428-w

  • CrossRef
  • Google Scholar

• 68

  Rodrigues TS de Sa KSG Ishimoto AY Becerra A Oliveira S Almeida L et al . Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med. (2021) 218:e20201707. doi: 10.1084/jem.20201707

  • CrossRef
  • Google Scholar

• 69

  Bass A Liu Y Dakshanamurthy S . Single-cell and bulk RNASeq profiling of COVID-19 patients reveal immune and inflammatory mechanisms of infection-induced organ damage. Viruses. (2021) 13:2418. doi: 10.3390/v13122418

  • CrossRef
  • Google Scholar

• 70

  Gomez-Rial J Rivero-Calle I Salas A Martinon-Torres F . Role of monocytes/macrophages in covid-19 pathogenesis: implications for therapy. Infect Drug Resist. (2020) 13:2485–93. doi: 10.2147/IDR.S258639

  • CrossRef
  • Google Scholar

• 71

  Knoll R Schultze JL Schulte-Schrepping J . Monocytes and macrophages in COVID-19. Front Immunol. (2021) 12:720109. doi: 10.3389/fimmu.2021.720109

  • CrossRef
  • Google Scholar

• 72

  Ryabkova VA Churilov LP Shoenfeld Y . Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned. Clin Immunol. (2021) 223:108652. doi: 10.1016/j.clim.2020.108652

  • CrossRef
  • Google Scholar

• 73

  Pacheco-Hernandez LM Ramirez-Noyola JA Gomez-Garcia IA Ignacio-Cortes S Zuniga J Choreno-Parra JA . Comparing the cytokine storms of COVID-19 and pandemic influenza. J Interferon Cytokine Res. (2022) 42:369–92. doi: 10.1089/jir.2022.0029

  • CrossRef
  • Google Scholar

• 74

  Sinha P Matthay MA Calfee CS . Is a “Cytokine storm” Relevant to COVID-19? JAMA Intern Med. (2020) 180:1152–4. doi: 10.1001/jamainternmed.2020.3313

  • CrossRef
  • Google Scholar

• 75

  Remy KE Mazer M Striker DA Ellebedy AH Walton AH Unsinger J et al . Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight. (2020) 5:e140329. doi: 10.1172/jci.insight.140329

  • CrossRef
  • Google Scholar

• 76

  Montazersaheb S Hosseiniyan Khatibi SM Hejazi MS Tarhriz V Farjami A Ghasemian Sorbeni F et al . COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. (2022) 19:92. doi: 10.1186/s12985-022-01814-1

  • CrossRef
  • Google Scholar

• 77

  Gajjela BK Zhou MM . Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. Drug Discovery Today. (2022) 27:390–400. doi: 10.1016/j.drudis.2021.10.016

  • CrossRef
  • Google Scholar

• 78

  Cron RQ Caricchio R Chatham WW . Calming the cytokine storm in COVID-19. Nat Med. (2021) 27:1674–5. doi: 10.1038/s41591-021-01500-9

  • CrossRef
  • Google Scholar

• 79

  Yang Y Shen C Li J Yuan J Wei J Huang F et al . Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. (2020) 146:119–27 e4. doi: 10.1016/j.jaci.2020.04.027

  • CrossRef
  • Google Scholar

• 80

  Han H Ma Q Li C Liu R Zhao L Wang W et al . Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. (2020) 9:1123–30. doi: 10.1080/22221751.2020.1770129

  • CrossRef
  • Google Scholar

• 81

  Del Valle-Mendoza J Tarazona-Castro Y Merino-Luna A Carrillo-Ng H Kym S Aguilar-Luis MA et al . Comparison of cytokines levels among COVID-19 patients living at sea level and high altitude. BMC Infect Dis. (2022) 22:96. doi: 10.1186/s12879-022-07079-x

  • CrossRef
  • Google Scholar

• 82

  Buszko M Nita-Lazar A Park JH Schwartzberg PL Verthelyi D Young HA et al . Lessons learned: new insights on the role of cytokines in COVID-19. Nat Immunol. (2021) 22:404–11. doi: 10.1038/s41590-021-00901-9

  • CrossRef
  • Google Scholar

• 83

  Olbei M Hautefort I Modos D Treveil A Poletti M Gul L et al . SARS-coV-2 causes a different cytokine response compared to other cytokine storm-causing respiratory viruses in severely ill patients. Front Immunol. (2021) 12:629193. doi: 10.3389/fimmu.2021.629193

  • CrossRef
  • Google Scholar

• 84

  Fahmy OH Daas FM Salunkhe V Petrey JL Cosar EF Ramirez J et al . Is microthrombosis the main pathology in coronavirus disease 2019 severity?-A systematic review of the postmortem pathologic findings. Crit Care Explor. (2021) 3:e0427. doi: 10.1097/CCE.0000000000000427

  • CrossRef
  • Google Scholar

• 85

  Hatton CF Botting RA Duenas ME Haq IJ Verdon B Thompson BJ et al . Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Nat Commun. (2021) 12:7092. doi: 10.1038/s41467-021-27318-0

  • CrossRef
  • Google Scholar

• 86

  Zhang Q Bastard P Liu Z Le Pen J Moncada-Velez M Chen J et al . Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. (2020) 370:eabd4570. doi: 10.1126/science.abd4570

  • CrossRef
  • Google Scholar

• 87

  Kehrer T Garcia-Sastre A Miorin L . Control of innate immune activation by severe acute respiratory syndrome coronavirus 2 and other coronaviruses. J Interferon Cytokine Res. (2021) 41:205–19. doi: 10.1089/jir.2021.0060

  • CrossRef
  • Google Scholar

• 88

  Schneider WM Chevillotte MD Rice CM . Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. (2014) 32:513–45. doi: 10.1146/annurev-immunol-032713-120231

  • CrossRef
  • Google Scholar

• 89

  Moss P . The T cell immune response against SARS-CoV-2. Nat Immunol. (2022) 23:186–93. doi: 10.1038/s41590-021-01122-w

  • CrossRef
  • Google Scholar

• 90

  Thoms M Buschauer R Ameismeier M Koepke L Denk T Hirschenberger M et al . Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science. (2020) 369:1249–55. doi: 10.1126/science.abc8665

  • CrossRef
  • Google Scholar

• 91

  Park A Iwasaki A . Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. (2020) 27:870–8. doi: 10.1016/j.chom.2020.05.008

  • CrossRef
  • Google Scholar

• 92

  Rose KM Elliott R Martinez-Sobrido L Garcia-Sastre A Weiss SR . Murine coronavirus delays expression of a subset of interferon-stimulated genes. J Virol. (2010) 84:5656–69. doi: 10.1128/JVI.00211-10

  • CrossRef
  • Google Scholar

• 93

  Zhang R Li Y Cowley TJ Steinbrenner AD Phillips JM Yount BL et al . The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM. WU. J Virol. (2015) 89:3598–609. doi: 10.1128/JVI.03535-14

  • CrossRef
  • Google Scholar

• 94

  Hadjadj J Yatim N Barnabei L Corneau A Boussier J Smith N et al . Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. (2020) 369:718–24. doi: 10.1126/science.abc6027

  • CrossRef
  • Google Scholar

• 95

  Hoagland DA Moller R Uhl SA Oishi K Frere J Golynker I et al . Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity. (2021) 54:557–70 e5. doi: 10.1016/j.immuni.2021.01.017

  • CrossRef
  • Google Scholar

• 96

  Stravalaci M Pagani I Paraboschi EM Pedotti M Doni A Scavello F et al . Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nat Immunol. (2022) 23:275–86. doi: 10.1038/s41590-021-01114-w

  • CrossRef
  • Google Scholar

• 97

  Holter JC Pischke SE de Boer E Lind A Jenum S Holten AR et al . Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci U S A. (2020) 117:25018–25. doi: 10.1073/pnas.2010540117

  • CrossRef
  • Google Scholar

• 98

  Smilowitz NR Kunichoff D Garshick M Shah B Pillinger M Hochman JS et al . C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. (2021) 42:2270–9. doi: 10.1093/eurheartj/ehaa1103

  • CrossRef
  • Google Scholar

• 99

  Sefik E Qu R Junqueira C Kaffe E Mirza H Zhao J et al . Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. (2022) 606:585–93. doi: 10.1038/s41586-022-04802-1

  • CrossRef
  • Google Scholar

• 100

  Park MD . Macrophages: a trojan horse in COVID-19? Nat Rev Immunol. (2020) 20:351. doi: 10.1038/s41577-020-0317-2

  • CrossRef
  • Google Scholar

• 101

  Abassi Z Knaney Y Karram T Heyman SN . The lung macrophage in SARS-coV-2 infection: A friend or a foe? Front Immunol. (2020) 11:1312. doi: 10.3389/fimmu.2020.01312

  • CrossRef
  • Google Scholar

• 102

  Pantazi I Al-Qahtani AA Alhamlan FS Alothaid H Matou-Nasri S Sourvinos G et al . SARS-coV-2/ACE2 interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages. Front Immunol. (2021) 12:683800. doi: 10.3389/fimmu.2021.683800

  • CrossRef
  • Google Scholar

• 103

  Yang D Chu H Hou Y Chai Y Shuai H Lee AC et al . Attenuated interferon and proinflammatory response in SARS-coV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. (2020) 222:734–45. doi: 10.1093/infdis/jiaa356

  • CrossRef
  • Google Scholar

• 104

  Laurent P Yang C Rendeiro AF Nilsson-Payant BE Carrau L Chandar V et al . Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. Sci Immunol. (2022) 7:eadd4906. doi: 10.1126/sciimmunol.add4906

  • CrossRef
  • Google Scholar

• 105

  Gordon S Pluddemann A . Tissue macrophages: heterogeneity and functions. BMC Biol. (2017) 15:53. doi: 10.1186/s12915-017-0392-4

  • CrossRef
  • Google Scholar

• 106

  Xu Q Yang Y Zhang X Cai JJ . Association of pyroptosis and severeness of COVID-19 as revealed by integrated single-cell transcriptome data analysis. Immunoinformatics (Amst). (2022) 6:100013. doi: 10.1016/j.immuno.2022.100013

  • CrossRef
  • Google Scholar

• 107

  Cervantes-Barragan L Zust R Weber F Spiegel M Lang KS Akira S et al . Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood. (2007) 109:1131–7. doi: 10.1182/blood-2006-05-023770

  • CrossRef
  • Google Scholar

• 108

  Venet M Ribeiro MS Decembre E Bellomo A Joshi G Nuovo C et al . Severe COVID-19 patients have impaired plasmacytoid dendritic cell-mediated control of SARS-CoV-2. Nat Commun. (2023) 14:694. doi: 10.1038/s41467-023-36140-9

  • CrossRef
  • Google Scholar

• 109

  Perez-Gomez A Vitalle J Gasca-Capote C Gutierrez-Valencia A Trujillo-Rodriguez M Serna-Gallego A et al . Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. Cell Mol Immunol. (2021) 18:2128–39. doi: 10.1038/s41423-021-00728-2

  • CrossRef
  • Google Scholar

• 110

  Galani IE Andreakos E . Neutrophils in viral infections: Current concepts and caveats. J Leukoc Biol. (2015) 98:557–64. doi: 10.1189/jlb.4VMR1114-555R

  • CrossRef
  • Google Scholar

• 111

  Ackermann M Anders HJ Bilyy R Bowlin GL Daniel C De Lorenzo R et al . Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ. (2021) 28:3125–39. doi: 10.1038/s41418-021-00805-z

  • CrossRef
  • Google Scholar

• 112

  Wu C Chen X Cai Y Xia J Zhou X Xu S et al . Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern Med. (2020) 180:934–43. doi: 10.1001/jamainternmed.2020.0994

  • CrossRef
  • Google Scholar

• 113

  Prozan L Shusterman E Ablin J Mitelpunkt A Weiss-Meilik A Adler A et al . Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection. Sci Rep. (2021) 11:21519. doi: 10.1038/s41598-021-00927-x

  • CrossRef
  • Google Scholar

• 114

  Liu Y Du X Chen J Jin Y Peng L Wang HHX et al . Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. (2020) 81:e6–e12. doi: 10.1016/j.jinf.2020.04.002

  • CrossRef
  • Google Scholar

• 115

  Schulte-Schrepping J Reusch N Paclik D Bassler K Schlickeiser S Zhang B et al . Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. (2020) 182:1419–40 e23. doi: 10.1016/j.cell.2020.08.001

  • CrossRef
  • Google Scholar

• 116

  O’Driscoll DN . Emergency myelopoiesis in critical illness: lessons from the COVID-19 pandemic. Ir J Med Sci. (2022) 192:831–2. doi: 10.1007/s11845-022-03068-w

  • CrossRef
  • Google Scholar

• 117

  Arcanjo A Logullo J Menezes CCB de Souza Carvalho Giangiarulo TC Dos Reis MC de Castro GMM et al . The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). Sci Rep. (2020) 10:19630. doi: 10.1038/s41598-020-76781-0

  • CrossRef
  • Google Scholar

• 118

  Vivier E Raulet DH Moretta A Caligiuri MA Zitvogel L Lanier LL et al . Innate or adaptive immunity? The example of natural killer cells. Science. (2011) 331:44–9. doi: 10.1126/science.1198687

  • CrossRef
  • Google Scholar

• 119

  Pituch-Noworolska AM . NK cells in SARS-CoV-2 infection. Cent Eur J Immunol. (2022) 47:95–101. doi: 10.5114/ceji.2022.113078

  • CrossRef
  • Google Scholar

• 120

  Diaz-Salazar C Sun JC . Coordinated viral control by cytotoxic lymphocytes ensures optimal adaptive NK cell responses. Cell Rep. (2020) 32:108186. doi: 10.1016/j.celrep.2020.108186

  • CrossRef
  • Google Scholar

• 121

  Maucourant C Filipovic I Ponzetta A Aleman S Cornillet M Hertwig L et al . Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. (2020) 5:eabd6832. doi: 10.1126/sciimmunol.abd6832

  • CrossRef
  • Google Scholar

• 122

  Bjorkstrom NK Ponzetta A . Natural killer cells and unconventional T cells in COVID-19. Curr Opin Virol. (2021) 49:176–82. doi: 10.1016/j.coviro.2021.06.005

  • CrossRef
  • Google Scholar

• 123

  Cifaldi L Prencipe G Caiello I Bracaglia C Locatelli F De Benedetti F et al . Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. (2015) 67:3037–46. doi: 10.1002/art.39295

  • CrossRef
  • Google Scholar

• 124

  Gustine JN Jones D . Immunopathology of hyperinflammation in COVID-19. Am J Pathol. (2021) 191:4–17. doi: 10.1016/j.ajpath.2020.08.009

  • CrossRef
  • Google Scholar

• 125

  Eberl G Colonna M Di Santo JP McKenzie AN . Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science. (2015) 348:aaa6566. doi: 10.1126/science.aaa6566

  • CrossRef
  • Google Scholar

• 126

  Silverstein NJ Wang Y Manickas-Hill Z Carbone C Dauphin A Boribong BP et al . Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. Elife. (2022) 11:e74681. doi: 10.7554/eLife.74681

  • CrossRef
  • Google Scholar

• 127

  Kuri-Cervantes L Pampena MB Meng W Rosenfeld AM Ittner CAG Weisman AR et al . Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol. (2020) 5:eabd7114. doi: 10.1126/sciimmunol.abd7114

  • CrossRef
  • Google Scholar

• 128

  Deschler S Kager J Erber J Fricke L Koyumdzhieva P Georgieva A et al . Mucosal-associated invariant T (MAIT) cells are highly activated and functionally impaired in COVID-19 patients. Viruses. (2021) 13:241. doi: 10.3390/v13020241

  • CrossRef
  • Google Scholar

• 129

  Flament H Rouland M Beaudoin L Toubal A Bertrand L Lebourgeois S et al . Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. (2021) 22:322–35. doi: 10.1038/s41590-021-00870-z

  • CrossRef
  • Google Scholar

• 130

  Toubal A Nel I Lotersztajn S Lehuen A . Mucosal-associated invariant T cells and disease. Nat Rev Immunol. (2019) 19:643–57. doi: 10.1038/s41577-019-0191-y

  • CrossRef
  • Google Scholar

• 131

  Singh K Cogan S Elekes S Murphy DM Cummins S Curran R et al . SARS-CoV-2 spike and nucleocapsid proteins fail to activate human dendritic cells or gammadelta T cells. PloS One. (2022) 17:e0271463. doi: 10.1371/journal.pone.0271463

  • CrossRef
  • Google Scholar

• 132

  Lo Presti E Dieli F Meraviglia S . Lymphopenia in COVID-19: gammadelta T cells-based therapeutic opportunities. Vaccines (Basel). (2021) 9:562. doi: 10.3390/vaccines9060562

  • CrossRef
  • Google Scholar

• 133

  von Massow G Oh S Lam A Gustafsson K . Gamma delta T cells and their involvement in COVID-19 virus infections. Front Immunol. (2021) 12:741218. doi: 10.3389/fimmu.2021.741218

  • CrossRef
  • Google Scholar

• 134

  Yazdanifar M Mashkour N Bertaina A . Making a case for using gammadelta T cells against SARS-CoV-2. Crit Rev Microbiol. (2020) 46:689–702. doi: 10.1080/1040841X.2020.1822279

  • CrossRef
  • Google Scholar

• 135

  Poccia F Agrati C Castilletti C Bordi L Gioia C Horejsh D et al . Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis. (2006) 193:1244–9. doi: 10.1086/502975

  • CrossRef
  • Google Scholar

• 136

  Lei L Qian H Yang X Zhang X Zhang D Dai T et al . The phenotypic changes of gammadelta T cells in COVID-19 patients. J Cell Mol Med. (2020) 24:11603–6. doi: 10.1111/jcmm.15620

  • CrossRef
  • Google Scholar

• 137

  Sette A Crotty S . Adaptive immunity to SARS-coV-2 and COVID-19. Cell. (2021) 184:861–80. doi: 10.1016/j.cell.2021.01.007

  • CrossRef
  • Google Scholar

• 138

  Tan L Wang Q Zhang D Ding J Huang Q Tang YQ et al . Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. (2020) 5:33. doi: 10.1038/s41392-020-0148-4

  • CrossRef
  • Google Scholar

• 139

  Yao C Bora SA Parimon T Zaman T Friedman OA Palatinus JA et al . Cell-type-specific immune dysregulation in severely ill COVID-19 patients. Cell Rep. (2021) 34:108590. doi: 10.1016/j.celrep.2020.108590

  • CrossRef
  • Google Scholar

• 140

  Gupta A Madhavan MV Sehgal K Nair N Mahajan S Sehrawat TS et al . Extrapulmonary manifestations of COVID-19. Nat Med. (2020) 26:1017–32. doi: 10.1038/s41591-020-0968-3

  • CrossRef
  • Google Scholar

• 141

  Xiang Q Feng Z Diao B Tu C Qiao Q Yang H et al . SARS-coV-2 induces lymphocytopenia by promoting inflammation and decimates secondary lymphoid organs. Front Immunol. (2021) 12:661052. doi: 10.3389/fimmu.2021.661052

  • CrossRef
  • Google Scholar

• 142

  Huang I Pranata R . Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. (2020) 8:36. doi: 10.1186/s40560-020-00453-4

  • CrossRef
  • Google Scholar

• 143

  Xu X Han M Li T Sun W Wang D Fu B et al . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. (2020) 117:10970–5. doi: 10.1073/pnas.2005615117

  • CrossRef
  • Google Scholar

• 144

  Diao B Wang C Tan Y Chen X Liu Y Ning L et al . Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. (2020) 11:827. doi: 10.3389/fimmu.2020.00827

  • CrossRef
  • Google Scholar

• 145

  Meckiff BJ Ramirez-Suastegui C Fajardo V Chee SJ Kusnadi A Simon H et al . Imbalance of regulatory and cytotoxic SARS-coV-2-reactive CD4(+) T cells in COVID-19. Cell. (2020) 183:1340–53 e16. doi: 10.1016/j.cell.2020.10.001

  • CrossRef
  • Google Scholar

• 146

  Grifoni A Weiskopf D Ramirez SI Mateus J Dan JM Moderbacher CR et al . Targets of T cell responses to SARS-coV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. (2020) 181:1489–501 e15. doi: 10.1016/j.cell.2020.05.015

  • CrossRef
  • Google Scholar

• 147

  Tan AT Linster M Tan CW Le Bert N Chia WN Kunasegaran K et al . Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. (2021) 34:108728. doi: 10.1016/j.celrep.2021.108728

  • CrossRef
  • Google Scholar

• 148

  Rydyznski Moderbacher C Ramirez SI Dan JM Grifoni A Hastie KM Weiskopf D et al . Antigen-specific adaptive immunity to SARS-coV-2 in acute COVID-19 and associations with age and disease severity. Cell. (2020) 183:996–1012 e19. doi: 10.1016/j.cell.2020.09.038

  • CrossRef
  • Google Scholar

• 149

  Sekine T Perez-Potti A Rivera-Ballesteros O Stralin K Gorin JB Olsson A et al . Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. (2020) 183:158–68 e14. doi: 10.1016/j.cell.2020.08.017

  • CrossRef
  • Google Scholar

• 150

  Gao M Liu Y Guo M Wang Q Wang Y Fan J et al . Regulatory CD4(+) and CD8(+) T cells are negatively correlated with CD4(+)/CD8(+) T cell ratios in patients acutely infected with SARS-CoV-2. J Leukoc Biol. (2021) 109:91–7. doi: 10.1002/JLB.5COVA0720-421RR

  • CrossRef
  • Google Scholar

• 151

  Kaneko N Kuo HH Boucau J Farmer JR Allard-Chamard H Mahajan VS et al . Loss of bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. (2020) 183:143–57 e13. doi: 10.1016/j.cell.2020.08.025

  • CrossRef
  • Google Scholar

• 152

  Basso K Dalla-Favera R . Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev. (2012) 247:172–83. doi: 10.1111/j.1600-065X.2012.01112.x

  • CrossRef
  • Google Scholar

• 153

  Maddur MS Miossec P Kaveri SV Bayry J . Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. (2012) 181:8–18. doi: 10.1016/j.ajpath.2012.03.044

  • CrossRef
  • Google Scholar

• 154

  Jones SA Hunter CA . Is IL-6 a key cytokine target for therapy in COVID-19? Nat Rev Immunol. (2021) 21:337–9. doi: 10.1038/s41577-021-00553-8

  • CrossRef
  • Google Scholar

• 155

  Martonik D Parfieniuk-Kowerda A Rogalska M Flisiak R . The role of th17 response in COVID-19. Cells. (2021) 10:1550. doi: 10.3390/cells10061550

  • CrossRef
  • Google Scholar

• 156

  Sadeghi A Tahmasebi S Mahmood A Kuznetsova M Valizadeh H Taghizadieh A et al . Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J Cell Physiol. (2021) 236:2829–39. doi: 10.1002/jcp.30047

  • CrossRef
  • Google Scholar

• 157

  Rha MS Shin EC . Activation or exhaustion of CD8(+) T cells in patients with COVID-19. Cell Mol Immunol. (2021) 18:2325–33. doi: 10.1038/s41423-021-00750-4

  • CrossRef
  • Google Scholar

• 158

  Nguyen THO Rowntree LC Petersen J Chua BY Hensen L Kedzierski L et al . CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity. (2021) 54:1066–82 e5. doi: 10.1016/j.immuni.2021.04.009

  • CrossRef
  • Google Scholar

• 159

  Varchetta S Mele D Oliviero B Mantovani S Ludovisi S Cerino A et al . Unique immunological profile in patients with COVID-19. Cell Mol Immunol. (2021) 18:604–12. doi: 10.1038/s41423-020-00557-9

  • CrossRef
  • Google Scholar

• 160

  Song JW Zhang C Fan X Meng FP Xu Z Xia P et al . Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. (2020) 11:3410. doi: 10.1038/s41467-020-17240-2

  • CrossRef
  • Google Scholar

• 161

  Mathew D Giles JR Baxter AE Oldridge DA Greenplate AR Wu JE et al . Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. (2020) 369:eabc8511. doi: 10.1126/science.abc8511

  • CrossRef
  • Google Scholar

• 162

  Swadling L Diniz MO Schmidt NM Amin OE Chandran A Shaw E et al . Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. (2022) 601:110–7. doi: 10.1038/s41586-021-04186-8

  • CrossRef
  • Google Scholar

• 163

  Grom AA Horne A De Benedetti F . Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. (2016) 12:259–68. doi: 10.1038/nrrheum.2015.179

  • CrossRef
  • Google Scholar

• 164

  Jung JH Rha MS Sa M Choi HK Jeon JH Seok H et al . SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat Commun. (2021) 12:4043. doi: 10.1038/s41467-021-24377-1

  • CrossRef
  • Google Scholar

• 165

  Wagner KI Mateyka LM Jarosch S Grass V Weber S Schober K et al . Recruitment of highly cytotoxic CD8(+) T cell receptors in mild SARS-CoV-2 infection. Cell Rep. (2022) 38:110214. doi: 10.1016/j.celrep.2021.110214

  • CrossRef
  • Google Scholar

• 166

  Adamo S Michler J Zurbuchen Y Cervia C Taeschler P Raeber ME et al . Signature of long-lived memory CD8(+) T cells in acute SARS-CoV-2 infection. Nature. (2022) 602:148–55. doi: 10.1038/s41586-021-04280-x

  • CrossRef
  • Google Scholar

• 167

  Buggert M Vella LA Nguyen S Wu VH Chen Z Sekine T et al . The identity of human tissue-emigrant CD8(+) T cells. Cell. (2020) 183:1946–61 e15. doi: 10.1016/j.cell.2020.11.019

  • CrossRef
  • Google Scholar

• 168

  Redd AD Nardin A Kared H Bloch EM Pekosz A Laeyendecker O et al . CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-coV-2 circulating variants. Open Forum Infect Dis. (2021) 8:ofab143. doi: 10.1093/ofid/ofab143

  • CrossRef
  • Google Scholar

• 169

  Keeton R Tincho MB Ngomti A Baguma R Benede N Suzuki A et al . T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. (2022) 603:488–92. doi: 10.1038/s41586-022-04460-3

  • CrossRef
  • Google Scholar

• 170

  Lu LL Suscovich TJ Fortune SM Alter G . Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. (2018) 18:46–61. doi: 10.1038/nri.2017.106

  • CrossRef
  • Google Scholar

• 171

  Dan JM Mateus J Kato Y Hastie KM Yu ED Faliti CE et al . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. (2021) 371:eabf4063. doi: 10.1126/science.abf4063

  • CrossRef
  • Google Scholar

• 172

  Lau EHY Tsang OTY Hui DSC Kwan MYW Chan WH Chiu SS et al . Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun. (2021) 12:63. doi: 10.1038/s41467-020-20247-4

  • CrossRef
  • Google Scholar

• 173

  Roltgen K Boyd SD . Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. (2021) 29:1063–75. doi: 10.1016/j.chom.2021.06.009

  • CrossRef
  • Google Scholar

• 174

  Embong AK Nguyen-Contant P Wang J Kanagaiah P Chaves FA Fitzgerald TF et al . Formation and expansion of memory B cells against coronavirus in acutely infected COVID-19 individuals. Pathogens. (2022) 11:186. doi: 10.3390/pathogens11020186

  • CrossRef
  • Google Scholar

• 175

  Morgenlander WR Henson SN Monaco DR Chen A Littlefield K Bloch EM et al . Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. J Clin Invest. (2021) 131:e146927. doi: 10.1172/JCI146927

  • CrossRef
  • Google Scholar

• 176

  Breiman A Ruven-Clouet N Le Pendu J . Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2. PloS Pathog. (2020) 16:e1008556. doi: 10.1371/journal.ppat.1008556

  • CrossRef
  • Google Scholar

• 177

  Pendu JL Breiman A Rocher J Dion M Ruvoen-Clouet N . ABO blood types and COVID-19: spurious, anecdotal, or truly important relationships? A reasoned review of available data. Viruses. (2021) 13:160. doi: 10.3390/v13020160

  • CrossRef
  • Google Scholar

• 178

  Severe Covid GG Ellinghaus D Degenhardt F Bujanda L Buti M Albillos A et al . Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med. (2020) 383:1522–34. doi: 10.1056/NEJMoa2020283

  • CrossRef
  • Google Scholar

• 179

  Roberts GHL Partha R Rhead B Knight SC Park DS Coignet MV et al . Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects. Nat Genet. (2022) 54:374–81. doi: 10.1038/s41588-022-01042-x

  • CrossRef
  • Google Scholar

• 180

  Boechat JL Chora I Morais A Delgado L . The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives. Pulmonology. (2021) 27:423–37. doi: 10.1016/j.pulmoe.2021.03.008

  • CrossRef
  • Google Scholar

• 181

  Woodruff MC Ramonell RP Nguyen DC Cashman KS Saini AS Haddad NS et al . Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. (2020) 21:1506–16. doi: 10.1038/s41590-020-00814-z

  • CrossRef
  • Google Scholar

• 182

  Long QX Liu BZ Deng HJ Wu GC Deng K Chen YK et al . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. (2020) 26:845–8. doi: 10.1038/s41591-020-0897-1

  • CrossRef
  • Google Scholar

• 183

  Iyer AS Jones FK Nodoushani A Kelly M Becker M Slater D et al . Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. (2020) 5:eabe0367. doi: 10.1126/sciimmunol.abe0367

  • CrossRef
  • Google Scholar

• 184

  Laidlaw BJ Ellebedy AH . The germinal centre B cell response to SARS-CoV-2. Nat Rev Immunol. (2022) 22:7–18. doi: 10.1038/s41577-021-00657-1

  • CrossRef
  • Google Scholar

• 185

  Muecksch F Wang Z Cho A Gaebler C Ben Tanfous T DaSilva J et al . Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. (2022) 607:128–34. doi: 10.1038/s41586-022-04778-y

  • CrossRef
  • Google Scholar

• 186

  Victora GD Nussenzweig MC . Germinal centers. Annu Rev Immunol. (2022) 40:413–42. doi: 10.1146/annurev-immunol-120419-022408

  • CrossRef
  • Google Scholar

• 187

  Pusnik J Richter E Schulte B Dolscheid-Pommerich R Bode C Putensen C et al . Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4(+) T cell help. Cell Rep. (2021) 35:109320. doi: 10.1016/j.celrep.2021.109320

  • CrossRef
  • Google Scholar

• 188

  Turner JS Kim W Kalaidina E Goss CW Rauseo AM Schmitz AJ et al . SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. (2021) 595:421–5. doi: 10.1038/s41586-021-03647-4

  • CrossRef
  • Google Scholar

• 189

  Halliley JL Tipton CM Liesveld J Rosenberg AF Darce J Gregoretti IV et al . Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity. (2015) 43:132–45. doi: 10.1016/j.immuni.2015.06.016

  • CrossRef
  • Google Scholar

• 190

  Heinz FX Stiasny K . Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. (2021) 6:104. doi: 10.1038/s41541-021-00369-6

  • CrossRef
  • Google Scholar

• 191

  Walsh EE Frenck RW Jr. Falsey AR Kitchin N Absalon J Gurtman A et al . Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. (2020) 383:2439–50. doi: 10.1056/NEJMoa2027906

  • CrossRef
  • Google Scholar

• 192

  Goel RR Painter MM Apostolidis SA Mathew D Meng W Rosenfeld AM et al . mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. (2021) 374:abm0829. doi: 10.1126/science.abm0829

  • CrossRef
  • Google Scholar

• 193

  Wherry EJ Barouch DH . T cell immunity to COVID-19 vaccines. Science. (2022) 377:821–2. doi: 10.1126/science.add2897

  • CrossRef
  • Google Scholar

• 194

  Chandrashekar A Yu J McMahan K Jacob-Dolan C Liu J He X et al . Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell. (2022) 185:1549–55 e11. doi: 10.1016/j.cell.2022.03.024

  • CrossRef
  • Google Scholar

• 195

  Liu J Chandrashekar A Sellers D Barrett J Jacob-Dolan C Lifton M et al . Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature. (2022) 603:493–6. doi: 10.1038/s41586-022-04465-y

  • CrossRef
  • Google Scholar

• 196

  Wong CKH Wong JYH Tang EHM Au CH Wai AKC . Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis. Sci Rep. (2020) 10:19765. doi: 10.1038/s41598-020-74988-9

  • CrossRef
  • Google Scholar

• 197

  Ho HT Peischard S Strutz-Seebohm N Klingel K Seebohm G . Myocardial damage by SARS-coV-2: emerging mechanisms and therapies. Viruses. (2021) 13:1880. doi: 10.3390/v13091880

  • CrossRef
  • Google Scholar

• 198

  Cui H Su S Cao Y Ma C Qiu W . The altered anatomical distribution of ACE2 in the brain with alzheimer’s disease pathology. Front Cell Dev Biol. (2021) 9:684874. doi: 10.3389/fcell.2021.684874

  • CrossRef
  • Google Scholar

• 199

  Jackson CB Farzan M Chen B Choe H . Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. (2022) 23:3–20. doi: 10.1038/s41580-021-00418-x

  • CrossRef
  • Google Scholar

• 200

  Thakur V Ratho RK Kumar P Bhatia SK Bora I Mohi GK et al . Multi-organ involvement in COVID-19: beyond pulmonary manifestations. J Clin Med. (2021) 10:446. doi: 10.3390/jcm10030446

  • CrossRef
  • Google Scholar

• 201

  Hikmet F Mear L Edvinsson A Micke P Uhlen M Lindskog C . The protein expression profile of ACE2 in human tissues. Mol Syst Biol. (2020) 16:e9610. doi: 10.15252/msb.20209610

  • CrossRef
  • Google Scholar

• 202

  Xu J Chu M Zhong F Tan X Tang G Mai J et al . Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell Death Discovery. (2020) 6:76. doi: 10.1038/s41420-020-00307-w

  • CrossRef
  • Google Scholar

• 203

  Albini A Calabrone L Carlini V Benedetto N Lombardo M Bruno A et al . Preliminary evidence for IL-10-induced ACE2 mRNA expression in lung-derived and endothelial cells: implications for SARS-cov-2 ARDS pathogenesis. Front Immunol. (2021) 12:718136. doi: 10.3389/fimmu.2021.718136

  • CrossRef
  • Google Scholar

• 204

  Guney C Akar F . Epithelial and endothelial expressions of ACE2: SARS-coV-2 entry routes. J Pharm Pharm Sci. (2021) 24:84–93. doi: 10.18433/jpps31455

  • CrossRef
  • Google Scholar

• 205

  Maccio U Zinkernagel AS Shambat SM Zeng X Cathomas G Ruschitzka F et al . SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine. (2021) 63:103182. doi: 10.1016/j.ebiom.2020.103182

  • CrossRef
  • Google Scholar

• 206

  Bois MC Boire NA Layman AJ Aubry MC Alexander MP Roden AC et al . COVID-19-associated nonocclusive fibrin microthrombi in the heart. Circulation. (2021) 143:230–43. doi: 10.1161/CIRCULATIONAHA.120.050754

  • CrossRef
  • Google Scholar

• 207

  Varga Z Flammer AJ Steiger P Haberecker M Andermatt R Zinkernagel AS et al . Endothelial cell infection and endotheliitis in COVID-19. Lancet. (2020) 395:1417–8. doi: 10.1016/S0140-6736(20)30937-5

  • CrossRef
  • Google Scholar

• 208

  Ackermann M Verleden SE Kuehnel M Haverich A Welte T Laenger F et al . Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. (2020) 383:120–8. doi: 10.1056/NEJMoa2015432

  • CrossRef
  • Google Scholar

• 209

  Ackermann M Mentzer SJ Kolb M Jonigk D . Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow. Eur Respir J. (2020) 56:2003147. doi: 10.1183/13993003.03147-2020

  • CrossRef
  • Google Scholar

• 210

  Kichloo A Dettloff K Aljadah M Albosta M Jamal S Singh J et al . COVID-19 and hypercoagulability: A review. Clin Appl Thromb Hemost. (2020) 26:1076029620962853. doi: 10.1177/1076029620962853

  • CrossRef
  • Google Scholar

• 211

  Lowenstein CJ Solomon SD . Severe COVID-19 is a microvascular disease. Circulation. (2020) 142:1609–11. doi: 10.1161/CIRCULATIONAHA.120.050354

  • CrossRef
  • Google Scholar

• 212

  Norooznezhad AH Mansouri K . Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19). Microvasc Res. (2021) 137:104188. doi: 10.1016/j.mvr.2021.104188

  • CrossRef
  • Google Scholar

• 213

  Middleton EA He XY Denorme F Campbell RA Ng D Salvatore SP et al . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. (2020) 136:1169–79. doi: 10.1182/blood.2020007008

  • CrossRef
  • Google Scholar

• 214

  Wu C Lu W Zhang Y Zhang G Shi X Hisada Y et al . Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity. (2019) 50:1401–11 e4. doi: 10.1016/j.immuni.2019.04.003

  • CrossRef
  • Google Scholar

• 215

  Gedefaw L Ullah S Leung PHM Cai Y Yip SP Huang CL . Inflammasome activation-induced hypercoagulopathy: impact on cardiovascular dysfunction triggered in COVID-19 patients. Cells. (2021) 10:916. doi: 10.3390/cells10040916

  • CrossRef
  • Google Scholar

• 216

  Grover SP Mackman N . Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. (2018) 38:709–25. doi: 10.1161/ATVBAHA.117.309846

  • CrossRef
  • Google Scholar

• 217

  Patra T Ray R . IL-6 induction and signaling: horizons of COVID-19-related pathogenesis. DNA Cell Biol. (2021) 40:639–42. doi: 10.1089/dna.2021.0152

  • CrossRef
  • Google Scholar

• 218

  Popescu NI Lupu C Lupu F . Disseminated intravascular coagulation and its immune mechanisms. Blood. (2022) 139:1973–86. doi: 10.1182/blood.2020007208

  • CrossRef
  • Google Scholar

• 219

  Torres Acosta MA Singer BD . Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur Respir J. (2020) 56:2002049. doi: 10.1183/13993003.02049-2020

  • CrossRef
  • Google Scholar

• 220

  Fuehner T Renger I Welte T Freundt T Gottlieb J . Silent hypoxia in COVID-19: A case series. Respiration. (2022) 101:376–80. doi: 10.1159/000520083

  • CrossRef
  • Google Scholar

• 221

  Simonson TS Baker TL Banzett RB Bishop T Dempsey JA Feldman JL et al . Silent hypoxaemia in COVID-19 patients. J Physiol. (2021) 599:1057–65. doi: 10.1113/JP280769

  • CrossRef
  • Google Scholar

• 222

  Karagiannidis C Hentschker C Westhoff M Weber-Carstens S Janssens U Kluge S et al . Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. PloS One. (2022) 17:e0262315. doi: 10.1371/journal.pone.0262315

  • CrossRef
  • Google Scholar

• 223

  Monteil V Kwon H Prado P Hagelkruys A Wimmer RA Stahl M et al . Inhibition of SARS-coV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. (2020) 181:905–13 e7. doi: 10.1016/j.cell.2020.04.004

  • CrossRef
  • Google Scholar

• 224

  Hsu CY Lai CC Yeh YP Chang-Chuan C Chen HH . Progression from pneumonia to ARDS as a predictor for fatal COVID-19. J Infect Public Health. (2021) 14:504–7. doi: 10.1016/j.jiph.2020.12.026

  • CrossRef
  • Google Scholar

• 225

  Elicker BM . What are the long-term pulmonary sequelae of COVID-19 infection? Radiology. (2022) 304:193–4. doi: 10.1148/radiol.220449

  • CrossRef
  • Google Scholar

• 226

  Gattinoni L Chiumello D Caironi P Busana M Romitti F Brazzi L et al . COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. (2020) 46:1099–102. doi: 10.1007/s00134-020-06033-2

  • CrossRef
  • Google Scholar

• 227

  Bos LDJ Sjoding M Sinha P Bhavani SV Lyons PG Bewley AF et al . Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Lancet Respir Med. (2021) 9:1377–86. doi: 10.1016/S2213-2600(21)00365-9

  • CrossRef
  • Google Scholar

• 228

  Haudebourg AF Perier F Tuffet S de Prost N Razazi K Mekontso Dessap A et al . Respiratory mechanics of COVID-19- versus non-COVID-19-associated acute respiratory distress syndrome. Am J Respir Crit Care Med. (2020) 202:287–90. doi: 10.1164/rccm.202004-1226LE

  • CrossRef
  • Google Scholar

• 229

  Bain W Yang H Shah FA Suber T Drohan C Al-Yousif N et al . COVID-19 versus non-COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes. Ann Am Thorac Soc. (2021) 18:1202–10. doi: 10.1513/AnnalsATS.202008-1026OC

  • CrossRef
  • Google Scholar

• 230

  Bos LDJ . COVID-19-related acute respiratory distress syndrome: not so atypical. Am J Respir Crit Care Med. (2020) 202:622–4. doi: 10.1164/rccm.202004-1423LE

  • CrossRef
  • Google Scholar

• 231

  Konopka KE Nguyen T Jentzen JM Rayes O Schmidt CJ Wilson AM et al . Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD. Histopathology. (2020) 77:570–8. doi: 10.1111/his.14180

  • CrossRef
  • Google Scholar

• 232

  Group RC Horby P Lim WS Emberson JR Mafham M Bell JL et al . Dexamethasone in hospitalized patients with covid-19. N Engl J Med. (2021) 384:693–704. doi: 10.1056/NEJMoa2021436

  • CrossRef
  • Google Scholar

• 233

  Villar J Ferrando C Martinez D Ambros A Munoz T Soler JA et al . Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. (2020) 8:267–76. doi: 10.1016/S2213-2600(19)30417-5

  • CrossRef
  • Google Scholar

• 234

  Hattori Y Hattori K Machida T Matsuda N . Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication. Biochem Pharmacol. (2022) 197:114909. doi: 10.1016/j.bcp.2022.114909

  • CrossRef
  • Google Scholar

• 235

  Haberecker M Schwarz EI Steiger P Frontzek K Scholkmann F Zeng X et al . Autopsy-based pulmonary and vascular pathology: pulmonary endotheliitis and multi-organ involvement in COVID-19 associated deaths. Respiration. (2022) 101:155–65. doi: 10.1159/000518914

  • CrossRef
  • Google Scholar

• 236

  Abou-Ismail MY Diamond A Kapoor S Arafah Y Nayak L . The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. (2020) 194:101–15. doi: 10.1016/j.thromres.2020.06.029

  • CrossRef
  • Google Scholar

• 237

  Investigators A Investigators AC-a Investigators R-C Lawler PR Goligher EC Berger JS et al . Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med. (2021) 385:790–802. doi: 10.1056/NEJMoa2105911

  • CrossRef
  • Google Scholar

• 238

  Langner RO Fuller GC . Collagen synthesis in thoracic aortas of rabbits with epinephrine-thyroxine induced arteriosclerosis. Atherosclerosis. (1973) 17:463–9. doi: 10.1016/0021-9150(73)90036-1

  • CrossRef
  • Google Scholar

• 239

  Gong X Yuan B Yuan Y . Incidence and prognostic value of pulmonary embolism in COVID-19: A systematic review and meta-analysis. PloS One. (2022) 17:e0263580. doi: 10.1371/journal.pone.0263580

  • CrossRef
  • Google Scholar

• 240

  Fraser M Agdamag ACC Maharaj VR Mutschler M Charpentier V Chowdhury M et al . COVID-19-associated myocarditis: an evolving concern in cardiology and beyond. Biol (Basel). (2022) 11:520. doi: 10.3390/biology11040520

  • CrossRef
  • Google Scholar

• 241

  Peretto G Villatore A Rizzo S Esposito A De Luca G Palmisano A et al . The spectrum of COVID-19-associated myocarditis: A patient-tailored multidisciplinary approach. J Clin Med. (2021) 10:1974. doi: 10.3390/jcm10091974

  • CrossRef
  • Google Scholar

• 242

  Haussner W DeRosa AP Haussner D Tran J Torres-Lavoro J Kamler J et al . COVID-19 associated myocarditis: A systematic review. Am J Emerg Med. (2022) 51:150–5. doi: 10.1016/j.ajem.2021.10.001

  • CrossRef
  • Google Scholar

• 243

  Oleszak F Maryniak A Botti E Abrahim C Salifu MO Youssef M et al . Myocarditis associated with COVID-19. Am J Med Case Rep. (2020) 8:498–502. doi: 10.12691/ajmcr-8-12-19

  • CrossRef
  • Google Scholar

• 244

  Boehmer TK Kompaniyets L Lavery AM Hsu J Ko JY Yusuf H et al . Association between COVID-19 and myocarditis using hospital-based administrative data - United States, march 2020-january 2021. MMWR Morb Mortal Wkly Rep. (2021) 70:1228–32. doi: 10.15585/mmwr.mm7035e5

  • CrossRef
  • Google Scholar

• 245

  Gauchotte G Venard V Segondy M Cadoz C Esposito-Fava A Barraud D et al . SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study. Int J Legal Med. (2021) 135:577–81. doi: 10.1007/s00414-020-02500-z

  • CrossRef
  • Google Scholar

• 246

  Wenzel P Kopp S Gobel S Jansen T Geyer M Hahn F et al . Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab. Cardiovasc Res. (2020) 116:1661–3. doi: 10.1093/cvr/cvaa160

  • CrossRef
  • Google Scholar

• 247

  Katsoularis I Fonseca-Rodriguez O Farrington P Lindmark K Fors Connolly AM . Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. (2021) 398:599–607. doi: 10.1016/S0140-6736(21)00896-5

  • CrossRef
  • Google Scholar

• 248

  Talanas G Dossi F Parodi G . Type 2 myocardial infarction in patients with coronavirus disease 2019. J Cardiovasc Med (Hagerstown). (2021) 22:603–5. doi: 10.2459/JCM.0000000000001136

  • CrossRef
  • Google Scholar

• 249

  Stefanini GG Montorfano M Trabattoni D Andreini D Ferrante G Ancona M et al . ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. (2020) 141:2113–6. doi: 10.1161/CIRCULATIONAHA.120.047525

  • CrossRef
  • Google Scholar

• 250

  Arhontoulis DC Kerr C Richards D Tjen K Hyams N Jones JA et al . Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries. bioRxiv. (2022) 16:799–811. doi: 10.1101/2022.01.31.478497

  • CrossRef
  • Google Scholar

• 251

  Beghi E Giussani G Westenberg E Allegri R Garcia-Azorin D Guekht A et al . Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. J Neurol. (2022) 269:2265–74. doi: 10.1007/s00415-021-10848-4

  • CrossRef
  • Google Scholar

• 252

  Chou SH Beghi E Helbok R Moro E Sampson J Altamirano V et al . Global incidence of neurological manifestations among patients hospitalized with COVID-19-A report for the GCS-neuroCOVID consortium and the ENERGY consortium. JAMA Netw Open. (2021) 4:e2112131. doi: 10.1001/jamanetworkopen.2021.12131

  • CrossRef
  • Google Scholar

• 253

  Merkler AE Parikh NS Mir S Gupta A Kamel H Lin E et al . Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol. (2020) 77:1–7. doi: 10.1001/jamaneurol.2020.2730

  • CrossRef
  • Google Scholar

• 254

  Nersesjan V Amiri M Christensen HK Benros ME Kondziella D . Thirty-Day Mortality and Morbidity in COVID-19 Positive vs. COVID-19 Negative Individuals and vs. Individuals Tested for Influenza A/B: A Population-Based Study. Front Med (Lausanne). (2020) 7:598272. doi: 10.3389/fmed.2020.598272

  • CrossRef
  • Google Scholar

• 255

  Varatharaj A Thomas N Ellul MA Davies NWS Pollak TA Tenorio EL et al . Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. (2020) 7:875–82. doi: 10.1016/S2215-0366(20)30287-X

  • CrossRef
  • Google Scholar

• 256

  Han Y Yuan K Wang Z Liu WJ Lu ZA Liu L et al . Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. Transl Psychiatry. (2021) 11:499. doi: 10.1038/s41398-021-01629-8

  • CrossRef
  • Google Scholar

• 257

  Heming M Li X Rauber S Mausberg AK Borsch AL Hartlehnert M et al . Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity. (2021) 54:164–75 e6. doi: 10.1016/j.immuni.2020.12.011

  • CrossRef
  • Google Scholar

• 258

  Franceschi AM Ahmed O Giliberto L Castillo M . Hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection. AJNR Am J Neuroradiol. (2020) 41:1173–6. doi: 10.3174/ajnr.A6595

  • CrossRef
  • Google Scholar

• 259

  Hartzell S Bin S Cantarelli C Haverly M Manrique J Angeletti A et al . Kidney failure associates with T cell exhaustion and imbalanced follicular helper T cells. Front Immunol. (2020) 11:583702. doi: 10.3389/fimmu.2020.583702

  • CrossRef
  • Google Scholar

• 260

  Cantarelli C Angeletti A Perin L Russo LS Sabiu G Podesta MA et al . Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. Clin Kidney J. (2022) 15:1816–28. doi: 10.1093/ckj/sfac174

  • CrossRef
  • Google Scholar

• 261

  Banham GD Godlee A Faustini SE Cunningham AF Richter A Harper L et al . Hemodialysis patients make long-lived antibodies against SARS-coV-2 that may be associated with reduced reinfection. J Am Soc Nephrol. (2021) 32:2140–2. doi: 10.1681/ASN.2021020188

  • CrossRef
  • Google Scholar

• 262

  Clarke CL Prendecki M Dhutia A Gan J Edwards C Prout V et al . Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. (2021) 99:1470–7. doi: 10.1016/j.kint.2021.03.009

  • CrossRef
  • Google Scholar

• 263

  Shankar S Beckett J Tipton T Ogbe A Kasanyinga M Dold C et al . SARS-coV-2-specific T cell responses are not associated with protection against reinfection in hemodialysis patients. J Am Soc Nephrol. (2022) 33:883–7. doi: 10.1681/ASN.2021121587

  • CrossRef
  • Google Scholar

• 264

  Aguilar-Bretones M den Hartog Y van Dijk LLA Malahe SRK Dieterich M Mora HT et al . SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity. NPJ Vaccines. (2024) 9:93. doi: 10.1038/s41541-024-00886-0

  • CrossRef
  • Google Scholar

• 265

  Pei G Zhang Z Peng J Liu L Zhang C Yu C et al . Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. (2020) 31:1157–65. doi: 10.1681/ASN.2020030276

  • CrossRef
  • Google Scholar

• 266

  Faour WH Choaib A Issa E Choueiry FE Shbaklo K Alhajj M et al . Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflammation Res. (2022) 71:39–56. doi: 10.1007/s00011-021-01520-8

  • CrossRef
  • Google Scholar

• 267

  Legrand M Bell S Forni L Joannidis M Koyner JL Liu K et al . Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol. (2021) 17:751–64. doi: 10.1038/s41581-021-00452-0

  • CrossRef
  • Google Scholar

• 268

  Sullivan MK Lees JS Drake TM Docherty AB Oates G Hardwick HE et al . Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study. Nephrol Dial Transplant. (2022) 37:271–84. doi: 10.1093/ndt/gfab303

  • CrossRef
  • Google Scholar

• 269

  Oetjens MT Luo JZ Chang A Leader JB Hartzel DN Moore BS et al . Electronic health record analysis identifies kidney disease as the leading risk factor for hospitalization in confirmed COVID-19 patients. PloS One. (2020) 15:e0242182. doi: 10.1371/journal.pone.0242182

  • CrossRef
  • Google Scholar

• 270

  May RM Cassol C Hannoudi A Larsen CP Lerma EV Haun RS et al . A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. (2021) 100:1303–15. doi: 10.1016/j.kint.2021.07.015

  • CrossRef
  • Google Scholar

• 271

  Nasr SH Kopp JB . COVID-19-associated collapsing glomerulopathy: an emerging entity. Kidney Int Rep. (2020) 5:759–61. doi: 10.1016/j.ekir.2020.04.030

  • CrossRef
  • Google Scholar

• 272

  Hassler L Batlle D . Potential SARS-CoV-2 kidney infection and paths to injury. Nat Rev Nephrol. (2022) 18:275–6. doi: 10.1038/s41581-022-00551-6

  • CrossRef
  • Google Scholar

• 273

  Velez JCQ Caza T Larsen CP . COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol. (2020) 16:565–7. doi: 10.1038/s41581-020-0332-3

  • CrossRef
  • Google Scholar

• 274

  Guimaraes Sousa S Kleiton de Sousa A Maria Carvalho Pereira C Sofia Miranda Loiola Araujo A de Aguiar Magalhaes D Vieira de Brito T et al . SARS-CoV-2 infection causes intestinal cell damage: Role of interferon’s imbalance. Cytokine. (2022) 152:155826. doi: 10.1016/j.cyto.2022.155826

  • CrossRef
  • Google Scholar

• 275

  Xu Y Li X Zhu B Liang H Fang C Gong Y et al . Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. (2020) 26:502–5. doi: 10.1038/s41591-020-0817-4

  • CrossRef
  • Google Scholar

• 276

  Feng Y Zeng D Hu L Yang Y Song S Shi Y et al . Case report: histopathology and molecular pathology analysis on enteric tissue of a COVID-19 patient. Diagn Pathol. (2021) 16:40. doi: 10.1186/s13000-021-01082-7

  • CrossRef
  • Google Scholar

• 277

  Blanco-Melo D Nilsson-Payant BE Liu WC Uhl S Hoagland D Moller R et al . Imbalanced host response to SARS-coV-2 drives development of COVID-19. Cell. (2020) 181:1036–45 e9. doi: 10.1016/j.cell.2020.04.026

  • CrossRef
  • Google Scholar

• 278

  Lamers MM Beumer J van der Vaart J Knoops K Puschhof J Breugem TI et al . SARS-CoV-2 productively infects human gut enterocytes. Science. (2020) 369:50–4. doi: 10.1126/science.abc1669

  • CrossRef
  • Google Scholar

• 279

  Saithong S Worasilchai N Saisorn W Udompornpitak K Bhunyakarnjanarat T Chindamporn A et al . Neutrophil extracellular traps in severe SARS-coV-2 infection: A possible impact of LPS and (1–>3)-beta-D-glucan in blood from gut translocation. Cells. (2022) 11:1103. doi: 10.3390/cells11071103

  • CrossRef
  • Google Scholar

• 280

  Kruglikov IL Scherer PE . Preexisting and inducible endotoxemia as crucial contributors to the severity of COVID-19 outcomes. PloS Pathog. (2021) 17:e1009306. doi: 10.1371/journal.ppat.1009306

  • CrossRef
  • Google Scholar

• 281

  Sun Z Song ZG Liu C Tan S Lin S Zhu J et al . Gut microbiome alterations and gut barrier dysfunction are associated with host immune homeostasis in COVID-19 patients. BMC Med. (2022) 20:24. doi: 10.1186/s12916-021-02212-0

  • CrossRef
  • Google Scholar

• 282

  Zhang F Lau RI Liu Q Su Q Chan FKL Ng SC . Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat Rev Gastroenterol Hepatol. (2023) 20:323–37. doi: 10.1038/s41575-022-00698-4

  • CrossRef
  • Google Scholar

• 283

  Chen C Haupert SR Zimmermann L Shi X Fritsche LG Mukherjee B . Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: A meta-analysis and systematic review. J Infect Dis. (2022) 226:1593–607. doi: 10.1093/infdis/jiac136

  • CrossRef
  • Google Scholar

• 284

  Ayoubkhani D Khunti K Nafilyan V Maddox T Humberstone B Diamond I et al . Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. (2021) 372:n693. doi: 10.1136/bmj.n693

  • CrossRef
  • Google Scholar

• 285

  Su Y Yuan D Chen DG Ng RH Wang K Choi J et al . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. (2022) 185:881–95 e20. doi: 10.1016/j.cell.2022.01.014

  • CrossRef
  • Google Scholar

• 286

  Groff D Sun A Ssentongo AE Ba DM Parsons N Poudel GR et al . Short-term and long-term rates of postacute sequelae of SARS-coV-2 infection: A systematic review. JAMA Netw Open. (2021) 4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568

  • CrossRef
  • Google Scholar

• 287

  Russell CD Lone NI Baillie JK . Comorbidities, multimorbidity and COVID-19. Nat Med. (2023) 29:334–43. doi: 10.1038/s41591-022-02156-9

  • CrossRef
  • Google Scholar

• 288

  Klein J Wood J Jaycox JR Dhodapkar RM Lu P Gehlhausen JR et al . Distinguishing features of Long COVID identified through immune profiling. Nature. (2023) 623:139–48. doi: 10.1038/s41586-023-06651-y

  • CrossRef
  • Google Scholar

• 289

  Stein SR Ramelli SC Grazioli A Chung JY Singh M Yinda CK et al . SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. (2022) 612:758–63. doi: 10.1038/s41586-022-05542-y

  • CrossRef
  • Google Scholar

• 290

  Swank Z Senussi Y Manickas-Hill Z Yu XG Li JZ Alter G et al . Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. (2022) 76:e487-90. doi: 10.1101/2022.06.14.22276401

  • CrossRef
  • Google Scholar

• 291

  Mantovani A Morrone MC Patrono C Santoro MG Schiaffino S Remuzzi G et al . Long Covid: where we stand and challenges ahead. Cell Death Differ. (2022) 29:1891–900. doi: 10.1038/s41418-022-01052-6

  • CrossRef
  • Google Scholar

• 292

  Davis HE McCorkell L Vogel JM Topol EJ . Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133–46. doi: 10.1038/s41579-023-00896-0

  • CrossRef
  • Google Scholar

• 293

  Griffin DE . Why does viral RNA sometimes persist after recovery from acute infections? PloS Biol. (2022) 20:e3001687. doi: 10.1371/journal.pbio.3001687

  • CrossRef
  • Google Scholar

• 294

  Kuhl U Pauschinger M Seeberg B Lassner D Noutsias M Poller W et al . Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. (2005) 112:1965–70. doi: 10.1161/CIRCULATIONAHA.105.548156

  • CrossRef
  • Google Scholar

• 295

  Gold JE Okyay RA Licht WE Hurley DJ . Investigation of long COVID prevalence and its relationship to epstein-barr virus reactivation. Pathogens. (2021) 10:763. doi: 10.3390/pathogens10060763

  • CrossRef
  • Google Scholar

• 296

  Bernal KDE Whitehurst CB . Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Virus Res. (2023) 334:199157. doi: 10.1016/j.virusres.2023.199157

  • CrossRef
  • Google Scholar

• 297

  Sepulveda N Malato J Sotzny F Grabowska AD Fonseca A Cordeiro C et al . Revisiting igG antibody reactivity to epstein-barr virus in myalgic encephalomyelitis/chronic fatigue syndrome and its potential application to disease diagnosis. Front Med (Lausanne). (2022) 9:921101. doi: 10.3389/fmed.2022.921101

  • CrossRef
  • Google Scholar

• 298

  Falzon D Zignol M Bastard M Floyd K Kasaeva T . The impact of the COVID-19 pandemic on the global tuberculosis epidemic. Front Immunol. (2023) 14:1234785. doi: 10.3389/fimmu.2023.1234785

  • CrossRef
  • Google Scholar

• 299

  Habib S Hamza E El-Gamal R Nosser NA Aboukamar WA Abdelsalam S et al . Clinical and immunological impacts of latent toxoplasmosis on COVID-19 patients. Cureus. (2023) 15:e45989. doi: 10.7759/cureus.45989

  • CrossRef
  • Google Scholar

• 300

  Hasichaolu Zhang X Li X Li X Li D . Circulating cytokines and lymphocyte subsets in patients who have recovered from COVID-19. BioMed Res Int. (2020) 2020:7570981. doi: 10.1155/2020/7570981

  • CrossRef
  • Google Scholar

• 301

  Phetsouphanh C Darley DR Wilson DB Howe A Munier CML Patel SK et al . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. (2022) 23:210–6. doi: 10.1038/s41590-021-01113-x

  • CrossRef
  • Google Scholar

• 302

  Schultheiss C Willscher E Paschold L Gottschick C Klee B Henkes SS et al . The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. (2022) 3:100663. doi: 10.1016/j.xcrm.2022.100663

  • CrossRef
  • Google Scholar

• 303

  Low RN Low RJ Akrami A . A review of cytokine-based pathophysiology of Long COVID symptoms. Front Med (Lausanne). (2023) 10:1011936. doi: 10.3389/fmed.2023.1011936

  • CrossRef
  • Google Scholar

• 304

  Zhao N Di B Xu LL . The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. (2021) 61:2–15. doi: 10.1016/j.cytogfr.2021.06.002

  • CrossRef
  • Google Scholar

• 305

  Shen HH Yang YX Meng X Luo XY Li XM Shuai ZW et al . NLRP3: A promising therapeutic target for autoimmune diseases. Autoimmun Rev. (2018) 17:694–702. doi: 10.1016/j.autrev.2018.01.020

  • CrossRef
  • Google Scholar

• 306

  Potere N Del Buono MG Caricchio R Cremer PC Vecchie A Porreca E et al . Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. EBioMedicine. (2022) 85:104299. doi: 10.1016/j.ebiom.2022.104299

  • CrossRef
  • Google Scholar

• 307

  Wang M Yu F Chang W Zhang Y Zhang L Li P . Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology. Front Immunol. (2023) 14:1185233. doi: 10.3389/fimmu.2023.1185233

  • CrossRef
  • Google Scholar

• 308

  Chang SE Feng A Meng W Apostolidis SA Mack E Artandi M et al . New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. (2021) 12:5417. doi: 10.1038/s41467-021-25509-3

  • CrossRef
  • Google Scholar

• 309

  Bastard P Rosen LB Zhang Q Michailidis E Hoffmann HH Zhang Y et al . Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. (2020) 370:eabd4585. doi: 10.1126/science.abd4585

  • CrossRef
  • Google Scholar

• 310

  Ahamed J Laurence J . Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest. (2022) 132:e161167. doi: 10.1172/JCI161167

  • CrossRef
  • Google Scholar

• 311

  De Biasi S Meschiari M Gibellini L Bellinazzi C Borella R Fidanza L et al . Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun. (2020) 11:3434. doi: 10.1038/s41467-020-17292-4

  • CrossRef
  • Google Scholar

• 312

  Cao J Wang C Zhang Y Lei G Xu K Zhao N et al . Integrated gut virome and bacteriome dynamics in COVID-19 patients. Gut Microbes. (2021) 13:1–21. doi: 10.1080/19490976.2021.1887722

  • CrossRef
  • Google Scholar

• 313

  Molloy EJ Nakra N Gale C Dimitriades VR Lakshminrusimha S . Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. Pediatr Res. (2023) 93:1499–508. doi: 10.1038/s41390-022-02263-w

  • CrossRef
  • Google Scholar

• 314

  Ahmad F Ahmed A Rajendraprasad SS Loranger A Gupta S Velagapudi M et al . Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection. Int J Infect Dis. (2021) 108:209–11. doi: 10.1016/j.ijid.2021.05.050

  • CrossRef
  • Google Scholar

• 315

  Godfred-Cato S Bryant B Leung J Oster ME Conklin L Abrams J et al . COVID-19-associated multisystem inflammatory syndrome in children - United States, march-july 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:1074–80. doi: 10.15585/mmwr.mm6932e2

  • CrossRef
  • Google Scholar

• 316

  Available online at: https://www.cdc.gov/mis/mis-a/hcp.html (Accessed December 02, 2022).

• 317

  Vogel TP Top KA Karatzios C Hilmers DC Tapia LI Moceri P et al . Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. (2021) 39:3037–49. doi: 10.1016/j.vaccine.2021.01.054

  • CrossRef
  • Google Scholar

• 318

  Sperotto F Friedman KG Son MBF VanderPluym CJ Newburger JW Dionne A . Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. (2021) 180:307–22. doi: 10.1007/s00431-020-03766-6

  • CrossRef
  • Google Scholar

• 319

  Shen M Milner A Foppiano Palacios C Ahmad T . Multisystem inflammatory syndrome in adults (MIS-A) associated with SARS-CoV-2 infection with delayed-onset myocarditis: case report. Eur Heart J Case Rep. (2021) 5:ytab470. doi: 10.1093/ehjcr/ytab470

  • CrossRef
  • Google Scholar

• 320

  Kaufmann CC Simon A Reinhart-Mikocki D Publig S Huber K Freynhofer MK . Multisystem inflammatory syndrome in adults in a young male following severe acute respiratory syndrome coronavirus-2 infection: a case report. Eur Heart J Case Rep. (2022) 6:ytab521. doi: 10.1093/ehjcr/ytab521

  • CrossRef
  • Google Scholar

• 321

  Aldeghaither S Qutob R Assanangkornchai N Issa-Chergui B Tam M Larotondo R et al . Clinical and histopathologic features of myocarditis in multisystem inflammatory syndrome (Adult)-associated COVID-19. Crit Care Explor. (2022) 10:e0630. doi: 10.1097/CCE.0000000000000630

  • CrossRef
  • Google Scholar

• 322

  McGrath LJ Scott AM Surinach A Chambers R Benigno M Malhotra D . Use of the postacute sequelae of COVID-19 diagnosis code in routine clinical practice in the US. JAMA Netw Open. (2022) 5:e2235089. doi: 10.1001/jamanetworkopen.2022.35089

  • CrossRef
  • Google Scholar

• 323

  Tsampasian V Elghazaly H Chattopadhyay R Debski M Naing TKP Garg P et al . Risk factors associated with post-COVID-19 condition: A systematic review and meta-analysis. JAMA Intern Med. (2023) 183:566–80. doi: 10.1001/jamainternmed.2023.0750

  • CrossRef
  • Google Scholar

• 324

  Xie Y Xu E Bowe B Al-Aly Z . Long-term cardiovascular outcomes of COVID-19. Nat Med. (2022) 28:583–90. doi: 10.1038/s41591-022-01689-3

  • CrossRef
  • Google Scholar

• 325

  Wan EYF Mathur S Zhang R Yan VKC Lai FTT Chui CSL et al . Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank. Cardiovasc Res. (2023) 119:1718–27. doi: 10.1093/cvr/cvac195

  • CrossRef
  • Google Scholar

• 326

  Han L Zhao S Li S Gu S Deng X Yang L et al . Excess cardiovascular mortality across multiple COVID-19 waves in the United States from March 2020 to March 2022. Nat Cardiovasc Res. (2023) 2:322–33. doi: 10.1038/s44161-023-00220-2

  • CrossRef
  • Google Scholar

• 327

  Daugherty SE Guo Y Heath K Dasmarinas MC Jubilo KG Samranvedhya J et al . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ. (2021) 373:n1098. doi: 10.1136/bmj.n1098

  • CrossRef
  • Google Scholar

• 328

  Abbasi J . The COVID heart-one year after SARS-coV-2 infection, patients have an array of increased cardiovascular risks. JAMA. (2022) 327:1113–4. doi: 10.1001/jama.2022.2411

  • CrossRef
  • Google Scholar

• 329

  Scudiero F Silverio A Muraca I Russo V Di Maio M Silvestro A et al . Long-term prognostic impact of right ventricular dysfunction in patients with COVID-19. J Pers Med. (2022) 12:162. doi: 10.3390/jpm12020162

  • CrossRef
  • Google Scholar

• 330

  Ruffenach G Hong J Vaillancourt M Medzikovic L Eghbali M . Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. Respir Res. (2020) 21:303. doi: 10.1186/s12931-020-01570-2

  • CrossRef
  • Google Scholar

• 331

  Simonneau G Galie N Rubin LJ Langleben D Seeger W Domenighetti G et al . Clinical classification of pulmonary hypertension. J Am Coll Cardiol. (2004) 43:5S–12S. doi: 10.1016/j.jacc.2004.02.037

  • CrossRef
  • Google Scholar

• 332

  Klok FA van der Hulle T den Exter PL Lankeit M Huisman MV Konstantinides S . The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. (2014) 28:221–6. doi: 10.1016/j.blre.2014.07.003

  • CrossRef
  • Google Scholar

• 333

  Cho JL Villacreses R Nagpal P Guo J Pezzulo AA Thurman AL et al . Quantitative chest CT assessment of small airways disease in post-acute SARS-coV-2 infection. Radiology. (2022) 304:185–92. doi: 10.1148/radiol.212170

  • CrossRef
  • Google Scholar

• 334

  Lewis KL Helgeson SA Tatari MM Mallea JM Baig HZ Patel NM . COVID-19 and the effects on pulmonary function following infection: A retrospective analysis. EClinicalMedicine. (2021) 39:101079. doi: 10.1016/j.eclinm.2021.101079

  • CrossRef
  • Google Scholar

• 335

  Faverio P Luppi F Rebora P D’Andrea G Stainer A Busnelli S et al . One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study. Respir Res. (2022) 23:65. doi: 10.1186/s12931-022-01994-y

  • CrossRef
  • Google Scholar

• 336

  Wild JM Porter JC Molyneaux PL George PM Stewart I Allen RJ et al . Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respir Res. (2021) 8:e001049. doi: 10.1136/bmjresp-2021-001049

  • CrossRef
  • Google Scholar

• 337

  Ambardar SR Hightower SL Huprikar NA Chung KK Singhal A Collen JF . Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J Clin Med. (2021) 10:2452. doi: 10.3390/jcm10112452

  • CrossRef
  • Google Scholar

• 338

  Tale S Ghosh S Meitei SP Kolli M Garbhapu AK Pudi S . Post-COVID-19 pneumonia pulmonary fibrosis. QJM. (2020) 113:837–8. doi: 10.1093/qjmed/hcaa255

  • CrossRef
  • Google Scholar

• 339

  Melms JC Biermann J Huang H Wang Y Nair A Tagore S et al . A molecular single-cell lung atlas of lethal COVID-19. Nature. (2021) 595:114–9. doi: 10.1038/s41586-021-03569-1

  • CrossRef
  • Google Scholar

• 340

  Li F Deng J Song Y Wu C Yu B Wang G et al . Pulmonary fibrosis in patients with COVID-19: A retrospective study. Front Cell Infect Microbiol. (2022) 12:1013526. doi: 10.3389/fcimb.2022.1013526

  • CrossRef
  • Google Scholar

• 341

  Davis HE Assaf GS McCorkell L Wei H Low RJ Re’em Y et al . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. doi: 10.1016/j.eclinm.2021.101019

  • CrossRef
  • Google Scholar

• 342

  Haider S Janowski AJ Lesnak JB Hayashi K Dailey DL Chimenti R et al . A comparison of pain, fatigue, and function between post-COVID-19 condition, fibromyalgia, and chronic fatigue syndrome: a survey study. Pain. (2023) 164:385–401. doi: 10.1097/j.pain.0000000000002711

  • CrossRef
  • Google Scholar

• 343

  Hellgren L Birberg Thornberg U Samuelsson K Levi R Divanoglou A Blystad I . Brain MRI and neuropsychological findings at long-term follow-up after COVID-19 hospitalisation: an observational cohort study. BMJ Open. (2021) 11:e055164. doi: 10.1136/bmjopen-2021-055164

  • CrossRef
  • Google Scholar

• 344

  Xu E Xie Y Al-Aly Z . Long-term neurologic outcomes of COVID-19. Nat Med. (2022) 28:2406–15. doi: 10.1038/s41591-022-02001-z

  • CrossRef
  • Google Scholar

• 345

  Spudich S Nath A . Nervous system consequences of COVID-19. Science. (2022) 375:267–9. doi: 10.1126/science.abm2052

  • CrossRef
  • Google Scholar

• 346

  Klein J Wood J Jaycox JR Dhodapkar RM Lu P Gehlhausen JR et al . Distinguishing features of long COVID identified through immune profiling. Nature. (2023) 623:139–48. doi: 10.1038/s41586-023-06651-y

  • CrossRef
  • Google Scholar

• 347

  Wong AC Devason AS Umana IC Cox TO Dohnalova L Litichevskiy L et al . Serotonin reduction in post-acute sequelae of viral infection. Cell. (2023) 186:4851–67 e20. doi: 10.1016/j.cell.2023.09.013

  • CrossRef
  • Google Scholar

• 348

  Mina Y Enose-Akahata Y Hammoud DA Videckis AJ Narpala SR O’Connell SE et al . Deep phenotyping of neurologic postacute sequelae of SARS-coV-2 infection. Neurol Neuroimmunol Neuroinflamm. (2023) 10:e200097. doi: 10.1212/NXI.0000000000200097

  • CrossRef
  • Google Scholar

• 349

  Greer N Bart B Billington CJ Diem SJ Ensrud KE Kaka A et al . COVID-19 postacute care major organ damage: a systematic review. BMJ Open. (2022) 12:e061245. doi: 10.1136/bmjopen-2022-061245

  • CrossRef
  • Google Scholar

• 350

  Al-Aly Z Xie Y Bowe B . High-dimensional characterization of post-acute sequelae of COVID-19. Nature. (2021) 594:259–64. doi: 10.1038/s41586-021-03553-9

  • CrossRef
  • Google Scholar

• 351

  Vanholder R Ringoir S . Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol. (1993) 3:1541–54. doi: 10.1681/ASN.V391541

  • CrossRef
  • Google Scholar

• 352

  Vaziri ND Pahl MV Crum A Norris K . Effect of uremia on structure and function of immune system. J Ren Nutr. (2012) 22:149–56. doi: 10.1053/j.jrn.2011.10.020

  • CrossRef
  • Google Scholar

• 353

  Yoon JW Pahl MV Vaziri ND . Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int. (2007) 71:167–72. doi: 10.1038/sj.ki.5002019

  • CrossRef
  • Google Scholar

• 354

  Yuan Q Tang B Zhang C . Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther. (2022) 7:182. doi: 10.1038/s41392-022-01036-5

  • CrossRef
  • Google Scholar

• 355

  Verkade MA van Druningen CJ Op de Hoek CT Weimar W Betjes MG . Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med. (2007) 7:65–71. doi: 10.1007/s10238-007-0127-x

  • CrossRef
  • Google Scholar

• 356

  Schiffl H Lang SM . Long-term interplay between COVID-19 and chronic kidney disease. Int Urol Nephrol. (2023) 55:1977–84. doi: 10.1007/s11255-023-03528-x

  • CrossRef
  • Google Scholar

• 357

  Uribarri A Nunez-Gil IJ Aparisi A Becerra-Munoz VM Feltes G Trabattoni D et al . Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. J Nephrol. (2020) 33:737–45. doi: 10.1007/s40620-020-00790-5

  • CrossRef
  • Google Scholar

• 358

  Coca SG Singanamala S Parikh CR . Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. (2012) 81:442–8. doi: 10.1038/ki.2011.379

  • CrossRef
  • Google Scholar

• 359

  Sato Y Takahashi M Yanagita M . Pathophysiology of AKI to CKD progression. Semin Nephrol. (2020) 40:206–15. doi: 10.1016/j.semnephrol.2020.01.011

  • CrossRef
  • Google Scholar

• 360

  Duffield JS . Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. (2014) 124:2299–306. doi: 10.1172/JCI72267

  • CrossRef
  • Google Scholar

• 361

  Yang L Besschetnova TY Brooks CR Shah JV Bonventre JV . Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. (2010) 16:535–43. doi: 10.1038/nm.2144

  • CrossRef
  • Google Scholar

• 362

  Kramann R Schneider RK DiRocco DP MaChado F Fleig S Bondzie PA et al . Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. (2015) 16:51–66. doi: 10.1016/j.stem.2014.11.004

  • CrossRef
  • Google Scholar

• 363

  Maksimowski N Williams VR Scholey JW . Kidney ACE2 expression: Implications for chronic kidney disease. PloS One. (2020) 15:e0241534. doi: 10.1371/journal.pone.0241534

  • CrossRef
  • Google Scholar

• 364

  Azinheira Nobrega Cruz N Goncalves de Oliveira LC Tedesco Silva Junior H Osmar Medina Pestana J Casarini DE . Angiotensin-converting enzyme 2 in the pathogenesis of renal abnormalities observed in COVID-19 patients. Front Physiol. (2021) 12:700220. doi: 10.3389/fphys.2021.700220

  • CrossRef
  • Google Scholar

• 365

  Tarris G de Rougemont A Estienney MA Journet J Lariotte AC Aubignat D et al . Chronic kidney disease linked to SARS-CoV-2 infection: a case report. BMC Nephrol. (2021) 22:278. doi: 10.1186/s12882-021-02490-z

  • CrossRef
  • Google Scholar

• 366

  Petersen EL Gossling A Adam G Aepfelbacher M Behrendt CA Cavus E et al . Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme. Eur Heart J. (2022) 43:1124–37. doi: 10.1093/eurheartj/ehab914

  • CrossRef
  • Google Scholar

• 367

  Nalbandian A Sehgal K Gupta A Madhavan MV McGroder C Stevens JS et al . Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601–15. doi: 10.1038/s41591-021-01283-z

  • CrossRef
  • Google Scholar

• 368

  Clarke SA Abbara A Dhillo WS . Impact of COVID-19 on the endocrine system: A mini-review. Endocrinology. (2022) 163:bqab203. doi: 10.1210/endocr/bqab203

  • CrossRef
  • Google Scholar

• 369

  Li K Chen G Hou H Liao Q Chen J Bai H et al . Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod BioMed Online. (2021) 42:260–7. doi: 10.1016/j.rbmo.2020.09.020

  • CrossRef
  • Google Scholar

• 370

  Sapra L Saini C Garg B Gupta R Verma B Mishra PK et al . Long-term implications of COVID-19 on bone health: pathophysiology and therapeutics. Inflammation Res. (2022) 71:1025–40. doi: 10.1007/s00011-022-01616-9

  • CrossRef
  • Google Scholar

• 371

  Zacharias H Dubey S Koduri G D’Cruz D . Rheumatological complications of covid 19. Autoimmun Rev. (2021) 20:102883. doi: 10.1016/j.autrev.2021.102883

  • CrossRef
  • Google Scholar

• 372

  Beydon M Chevalier K Al Tabaa O Hamroun S Delettre AS Thomas M et al . Myositis as a manifestation of SARS-coV-2. Ann Rheum Dis. (2021) 80:e42. doi: 10.1136/annrheumdis-2020-217573

  • CrossRef
  • Google Scholar

• 373

  Fiolet T Kherabi Y MacDonald CJ Ghosn J Peiffer-Smadja N . Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. (2022) 28:202–21. doi: 10.1016/j.cmi.2021.10.005

  • CrossRef
  • Google Scholar

• 374

  Forchette L Sebastian W Liu T . A comprehensive review of COVID-19 virology, vaccines, variants, and therapeutics. Curr Med Sci. (2021) 41:1037–51. doi: 10.1007/s11596-021-2395-1

  • CrossRef
  • Google Scholar

• 375

  Mendiola-Pastrana IR Lopez-Ortiz E Rio de la Loza-Zamora JG Gonzalez J Gomez-Garcia A Lopez-Ortiz G . SARS-coV-2 variants and clinical outcomes: A systematic review. Life (Basel). (2022) 12:170. doi: 10.3390/life12020170

  • CrossRef
  • Google Scholar

• 376

  Corriero A Ribezzi M Mele F Angrisani C Romaniello F Daleno A et al . COVID-19 variants in critically ill patients: A comparison of the delta and omicron variant profiles. Infect Dis Rep. (2022) 14:492–500. doi: 10.3390/idr14030052

  • CrossRef
  • Google Scholar

• 377

  Du M Ma Y Deng J Liu M Liu J . Comparison of long COVID-19 caused by different SARS-coV-2 strains: A systematic review and meta-analysis. Int J Environ Res Public Health. (2022) 19:16010. doi: 10.3390/ijerph192316010

  • CrossRef
  • Google Scholar

• 378

  Notarte KI Catahay JA Velasco JV Pastrana A Ver AT Pangilinan FC et al . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. (2022) 53:101624. doi: 10.1016/j.eclinm.2022.101624

  • CrossRef
  • Google Scholar

• 379

  Byambasuren O Stehlik P Clark J Alcorn K Glasziou P . Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. (2023) 2:e000385. doi: 10.1136/bmjmed-2022-000385

  • CrossRef
  • Google Scholar

• 380

  Tyrkalska SD Martinez-Lopez A Arroyo AB Martinez-Morcillo FJ Candel S Garcia-Moreno D et al . Differential proinflammatory activities of Spike proteins of SARS-CoV-2 variants of concern. Sci Adv. (2022) 8:eabo0732. doi: 10.1126/sciadv.abo0732

  • CrossRef
  • Google Scholar

• 381

  Nishijima Y Hader SN Hanson AJ Zhang DX Sparapani R Gutterman DD et al . Prolonged endothelial-dysfunction in human arterioles following infection with SARS-CoV-2. Cardiovasc Res. (2022) 118:18–9. doi: doi.org/10.1093/cvr/cvab339

  • Google Scholar

• 382

  Nishijima Y Hader SN Beyer AM . Differential impacts of COVID-19 variants on human microvascular function. Cardiovasc Res. (2023) 119:e115–e7. doi: 10.1093/cvr/cvad006

  • CrossRef
  • Google Scholar

• 383

  Jiang Y Rubin L Peng T Liu L Xing X Lazarovici P et al . Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci. (2022) 18:459–72. doi: 10.7150/ijbs.59272

  • CrossRef
  • Google Scholar

• 384

  Henderson LA Canna SW Schulert GS Volpi S Lee PY Kernan KF et al . On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. (2020) 72:1059–63. doi: 10.1002/art.41285

  • CrossRef
  • Google Scholar

• 385

  Chen X Zhao B Qu Y Chen Y Xiong J Feng Y et al . Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis. (2020) 71:1937–42. doi: 10.1093/cid/ciaa449

  • CrossRef
  • Google Scholar

• 386

  Luporini RL Rodolpho JMA Kubota LT Martin A Cominetti MR Anibal FF et al . IL-6 and IL-10 are associated with disease severity and higher comorbidity in adults with COVID-19. Cytokine. (2021) 143:155507. doi: 10.1016/j.cyto.2021.155507

  • CrossRef
  • Google Scholar

• 387

  Bekele Y Sui Y Berzofsky JA . IL-7 in SARS-coV-2 infection and as a potential vaccine adjuvant. Front Immunol. (2021) 12:737406. doi: 10.3389/fimmu.2021.737406

  • CrossRef
  • Google Scholar

• 388

  Ma A Zhang L Ye X Chen J Yu J Zhuang L et al . High levels of circulating IL-8 and soluble IL-2R are associated with prolonged illness in patients with severe COVID-19. Front Immunol. (2021) 12:626235. doi: 10.3389/fimmu.2021.626235

  • CrossRef
  • Google Scholar

• 389

  Kedor C Freitag H Meyer-Arndt L Wittke K Hanitsch LG Zoller T et al . A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. (2022) 13:5104. doi: 10.1038/s41467-022-32507-6

  • CrossRef
  • Google Scholar

• 390

  Shabgah AG Navashenaq JG Shabgah OG Mohammadi H Sahebkar A . Interleukin-22 in human inflammatory diseases and viral infections. Autoimmun Rev. (2017) 16:1209–18. doi: 10.1016/j.autrev.2017.10.004

  • CrossRef
  • Google Scholar

• 391

  Fang S Ju D Lin Y Chen W . The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. Front Immunol. (2022) 13:951107. doi: 10.3389/fimmu.2022.951107

  • CrossRef
  • Google Scholar

• 392

  Muller U Steinhoff U Reis LF Hemmi S Pavlovic J Zinkernagel RM et al . Functional role of type I and type II interferons in antiviral defense. Science. (1994) 264:1918–21. doi: 10.1126/science.8009221

  • CrossRef
  • Google Scholar

• 393

  Lee JS Shin EC . The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. (2020) 20:585–6. doi: 10.1038/s41577-020-00429-3

  • CrossRef
  • Google Scholar

• 394

  Karki R Sharma BR Tuladhar S Williams EP Zalduondo L Samir P et al . Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-coV-2 infection and cytokine shock syndromes. Cell. (2021) 184:149–68 e17. doi: 10.1016/j.cell.2020.11.025

  • CrossRef
  • Google Scholar

• 395

  Rubtsova K Rubtsov AV Cancro MP Marrack P . Age-associated B cells: A T-bet-dependent effector with roles in protective and pathogenic immunity. J Immunol. (2015) 195:1933–7. doi: 10.4049/jimmunol.1501209

  • CrossRef
  • Google Scholar

• 396

  Ferreira-Gomes M Kruglov A Durek P Heinrich F Tizian C Heinz GA et al . SARS-CoV-2 in severe COVID-19 induces a TGF-beta-dominated chronic immune response that does not target itself. Nat Commun. (2021) 12:1961. doi: 10.1038/s41467-021-22210-3

  • CrossRef
  • Google Scholar

• 397

  Witkowski M Tizian C Ferreira-Gomes M Niemeyer D Jones TC Heinrich F et al . Untimely TGFbeta responses in COVID-19 limit antiviral functions of NK cells. Nature. (2021) 600:295–301. doi: 10.1038/s41586-021-04142-6

  • CrossRef
  • Google Scholar

• 398

  Wilk AJ Rustagi A Zhao NQ Roque J Martinez-Colon GJ McKechnie JL et al . A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. (2020) 26:1070–6. doi: 10.1038/s41591-020-0944-y

  • CrossRef
  • Google Scholar

• 399

  Parrot T Gorin JB Ponzetta A Maleki KT Kammann T Emgard J et al . MAIT cell activation and dynamics associated with COVID-19 disease severity. Sci Immunol. (2020) 5:eabe1670. doi: 10.1101/2020.08.27.20182550

  • CrossRef
  • Google Scholar

• 400

  Townsend L Dyer AH Naughton A Imangaliyev S Dunne J Kiersey R et al . Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Heliyon. (2022) 8:e09230. doi: 10.1016/j.heliyon.2022.e09230

  • CrossRef
  • Google Scholar

• 401

  George PM Reed A Desai SR Devaraj A Faiez TS Laverty S et al . A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae. Sci Transl Med. (2022) 14:eabo5795. doi: 10.1126/scitranslmed.abo5795

  • CrossRef
  • Google Scholar

• 402

  Zhu Y Chen X Liu X . NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond. Front Immunol. (2022) 13:838011. doi: 10.3389/fimmu.2022.838011

  • CrossRef
  • Google Scholar

• 403

  Newell KL Clemmer DC Cox JB Kayode YI Zoccoli-Rodriguez V Taylor HE et al . Switched and unswitched memory B cells detected during SARS-CoV-2 convalescence correlate with limited symptom duration. PloS One. (2021) 16:e0244855. doi: 10.1371/journal.pone.0244855

  • CrossRef
  • Google Scholar

• 404

  Speletas M Dadouli K Syrakouli A Gatselis N Germanidis G Mouchtouri VA et al . MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19. Immunobiology. (2021) 226:152136. doi: 10.1016/j.imbio.2021.152136

  • CrossRef
  • Google Scholar

• 405

  Terahara K Sato T Adachi Y Tonouchi K Onodera T Moriyama S et al . SARS-CoV-2-specific CD4(+) T cell longevity correlates with Th17-like phenotype. iScience. (2022) 25:104959. doi: 10.1016/j.isci.2022.104959

  • CrossRef
  • Google Scholar

• 406

  Ryan FJ Hope CM Masavuli MG Lynn MA Mekonnen ZA Yeow AEL et al . Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. (2022) 20:26. doi: 10.1186/s12916-021-02228-6

  • CrossRef
  • Google Scholar

• 407

  Guo L Wang G Wang Y Zhang Q Ren L Gu X et al . SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. (2022) 3:e348–e56. doi: 10.1016/S2666-5247(22)00036-2

  • CrossRef
  • Google Scholar

• 408

  Al-Saadi E Abdulnabi MA . Hematological changes associated with COVID-19 infection. J Clin Lab Anal. (2022) 36:e24064. doi: 10.1002/jcla.24064

  • CrossRef
  • Google Scholar

• 409

  Terpos E Ntanasis-Stathopoulos I Elalamy I Kastritis E Sergentanis TN Politou M et al . Hematological findings and complications of COVID-19. Am J Hematol. (2020) 95:834–47. doi: 10.1002/ajh.25829

  • CrossRef
  • Google Scholar

• 410

  Halpert G Shoenfeld Y . SARS-CoV-2, the autoimmune virus. Autoimmun Rev. (2020) 19:102695. doi: 10.1016/j.autrev.2020.102695

  • CrossRef
  • Google Scholar

• 411

  Pretorius E Vlok M Venter C Bezuidenhout JA Laubscher GJ Steenkamp J et al . Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. (2021) 20:172. doi: 10.1186/s12933-021-01359-7

  • CrossRef
  • Google Scholar

• 412

  Salisbury R Iotchkova V Jaafar S Morton J Sangha G Shah A et al . Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up. Blood Adv. (2020) 4:6230–9. doi: 10.1182/bloodadvances.2020003349

  • CrossRef
  • Google Scholar

• 413

  Munipalli B Seim L Dawson NL Knight D Dabrh AMA . Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management. SN Compr Clin Med. (2022) 4:90. doi: 10.1007/s42399-022-01167-4

  • CrossRef
  • Google Scholar

• 414

  Jewell PD Bramham K Galloway J Post F Norton S Teo J et al . COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. BMC Nephrol. (2021) 22:359. doi: 10.1186/s12882-021-02557-x

  • CrossRef
  • Google Scholar

• 415

  Credle JJ Gunn J Sangkhapreecha P Monaco DR Zheng XA Tsai HJ et al . Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. Nat Biomed Eng. (2022) 6(8):992–1003. doi: 10.1038/s41551-022-00925-y

  • CrossRef
  • Google Scholar